[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 10496
1. Bayona C, Lassaletta A, Pérez A, Sevilla J, Albi G, Villa JR, Madero L: [Fatal hemoptysis secondary to invasive pulmonary aspergillosis in a girl with acute myeloblastic leukemia]. An Pediatr (Barc); 2007 Sep;67(3):278-9
MedlinePlus Health Information. consumer health - Aspergillosis.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Fatal hemoptysis secondary to invasive pulmonary aspergillosis in a girl with acute myeloblastic leukemia].
  • [Transliterated title] Hemoptisis fatal secundaria a aspergilosis pulmonar invasiva en una paciente con leucemia mieloblástica aguda.
  • [MeSH-major] Aspergillosis / complications. Hemoptysis / etiology. Leukemia, Myeloid, Acute / complications. Lung Diseases, Fungal / complications

  • Genetic Alliance. consumer health - Aspergillosis.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17785168.001).
  • [ISSN] 1695-4033
  • [Journal-full-title] Anales de pediatría (Barcelona, Spain : 2003)
  • [ISO-abbreviation] An Pediatr (Barc)
  • [Language] spa
  • [Publication-type] Case Reports; Letter
  • [Publication-country] Spain
  •  go-up   go-down


2. Kakkar N, Das S, Joseph JM: Pseudo Chediak Higashi inclusions in a patient with acute myeloblastic leukemia. Indian J Cancer; 2010 Jan-Mar;47(1):81-2
MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pseudo Chediak Higashi inclusions in a patient with acute myeloblastic leukemia.
  • [MeSH-major] Inclusion Bodies / pathology. Leukemia, Myeloid, Acute / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20071802.001).
  • [ISSN] 1998-4774
  • [Journal-full-title] Indian journal of cancer
  • [ISO-abbreviation] Indian J Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] India
  •  go-up   go-down


3. Burke LP, Kukoly CA: Statins induce lethal effects in acute myeloblastic leukemia [corrected] cells within 72 hours. Leuk Lymphoma; 2008 Feb;49(2):322-30
Hazardous Substances Data Bank. LOVASTATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Statins induce lethal effects in acute myeloblastic leukemia [corrected] cells within 72 hours.
  • HMG-CoA Reductase inhibitors (statins) induce apoptosis in acute myeloid leukemia (AML) cells in vitro; however, the concentrations associated with cell death in AML cells are higher than those clinically tolerated during prolonged therapy.
  • We therefore wished to determine whether short exposures to lovastatin might induce cell death in AML cells at clinically attainable concentrations.
  • The time and concentration dependence of HL60 and U937 cells was determined and showed that cell death was delayed.
  • IC(50) values and IC(90) values determined on day 6 suggested that the sensitivity of AML cells to statins may occur at lower concentrations than previously reported.
  • After 72 h, mevalonate did not rescue AML cells from cytotoxic concentrations of statins, suggesting that, although cell death was delayed, lovastatin induced lethal effects within 72 h.
  • In conjunction with previously reported Phase I studies, the data presented here suggest that the high-dose, short course statins may be useful for the treatment of patients with AML.
  • [MeSH-major] Apoptosis / drug effects. Hydroxymethylglutaryl-CoA Reductase Inhibitors / pharmacology. Leukemia, Myeloid, Acute / drug therapy
  • [MeSH-minor] Cell Line, Tumor. Dose-Response Relationship, Drug. Drug Screening Assays, Antitumor. Humans. Lovastatin / pharmacology. Mevalonic Acid / pharmacology

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • MedlinePlus Health Information. consumer health - Statins.
  • Hazardous Substances Data Bank. MEVALONIC ACID .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Neoplasma. 1997;44(6):366-9 [9605009.001]
  • [Cites] Toxicol Pathol. 1996 Jul-Aug;24(4):468-76 [8864188.001]
  • [Cites] Clin Cancer Res. 1996 Mar;2(3):483-91 [9816194.001]
  • [Cites] Blood. 1999 Feb 15;93(4):1308-18 [9949174.001]
  • [Cites] Toxicol Pathol. 1999 Jul-Aug;27(4):395-401 [10485819.001]
  • [Cites] Eur J Cancer. 2005 Mar;41(4):523-30 [15737556.001]
  • [Cites] N Engl J Med. 2005 May 26;352(21):2184-92 [15917383.001]
  • [Cites] Cancer Chemother Pharmacol. 2006 Jan;57(2):155-64 [16133537.001]
  • [Cites] JAMA. 2006 Jan 4;295(1):74-80 [16391219.001]
  • [Cites] Haematologica. 2006 Apr;91(4):542-5 [16585018.001]
  • [Cites] Blood. 2007 Apr 1;109(7):2999-3006 [17158228.001]
  • [Cites] Br J Haematol. 1998 Jul;102(2):522-7 [9695968.001]
  • [Cites] Leukemia. 2000 Aug;14(8):1444-50 [10942241.001]
  • [Cites] Acta Haematol. 2000;104(2-3):72-9 [11154978.001]
  • [Cites] Leuk Res. 2001 Aug;25(8):651-60 [11397469.001]
  • [Cites] Leuk Lymphoma. 2000 Dec;40(1-2):167-78 [11426618.001]
  • [Cites] J Investig Med. 2001 Jul;49(4):319-24 [11478407.001]
  • [Cites] Leukemia. 2001 Sep;15(9):1398-407 [11516100.001]
  • [Cites] Leukemia. 2002 Apr;16(4):508-19 [11960327.001]
  • [Cites] Leuk Lymphoma. 2002 Jun;43(6):1221-8 [12152989.001]
  • [Cites] Leuk Res. 2003 Feb;27(2):133-45 [12526919.001]
  • [Cites] Clin Cancer Res. 2003 Jan;9(1):10-9 [12538446.001]
  • [Cites] Blood. 2003 May 1;101(9):3628-34 [12506040.001]
  • [Cites] Endocrinology. 2003 Sep;144(9):3852-9 [12933658.001]
  • [Cites] J Am Coll Cardiol. 2004 Aug 4;44(3):720-32 [15358046.001]
  • [Cites] J Biol Chem. 1990 Feb 5;265(4):2148-55 [2105317.001]
  • [Cites] Anticancer Drugs. 1994 Oct;5(5):598-600 [7858293.001]
  • [Cites] Methods Enzymol. 1995;255:237-45 [8524107.001]
  • [Cites] Nat Med. 1996 Mar;2(3):326-33 [8612233.001]
  • [Cites] Biochem Mol Biol Int. 1996 Feb;38(2):345-55 [8850530.001]
  • [ErratumIn] Leuk Lymphoma. 2008 Apr;49(4):832
  • (PMID = 18231920.001).
  • [ISSN] 1029-2403
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Hydroxymethylglutaryl-CoA Reductase Inhibitors; 9LHU78OQFD / Lovastatin; S5UOB36OCZ / Mevalonic Acid
  • [Other-IDs] NLM/ PMC2430172
  •  go-up   go-down


Advertisement
4. Siitonen T, Koistinen P, Savolainen ER: Increase in Ara-C cytotoxicity in the presence of valproate, a histone deacetylase inhibitor, is associated with the concurrent expression of cyclin D1 and p27(Kip 1) in acute myeloblastic leukemia cells. Leuk Res; 2005 Nov;29(11):1335-42
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Increase in Ara-C cytotoxicity in the presence of valproate, a histone deacetylase inhibitor, is associated with the concurrent expression of cyclin D1 and p27(Kip 1) in acute myeloblastic leukemia cells.
  • The effects of valproate and butyrate were investigated in an acute myeloblastic cell line (OCI/AML-2) on cytotoxicity, cell cycle profile and expression of cell cycle regulating proteins in the presence of cytarabine (Ara-C) and etoposide.
  • As a single agent valproate and butyrate inhibited AML cell growth but did not significantly induce cell death.
  • A dramatic increase in cytotoxicity was observed when combining valproate or butyrate with Ara-C, whereas, co-addition of them with etoposide had much smaller effect on cell death.
  • In addition, valporate was able to block the Ara-C-induced down-regulation of p27(Kip1) expression but not that induced by etoposide.
  • [MeSH-major] Cyclin D1 / biosynthesis. Cyclin-Dependent Kinase Inhibitor p27 / biosynthesis. Cytarabine / pharmacology. Enzyme Inhibitors / pharmacology. Histone Deacetylase Inhibitors. Leukemia, Myeloid, Acute / metabolism. Valproic Acid / pharmacology
  • [MeSH-minor] Butyrates / pharmacology. Cell Cycle / drug effects. Cell Death / drug effects. Cell Line, Tumor. Cell Proliferation / drug effects. Cell Survival / drug effects. Etoposide / pharmacology. Humans

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. VALPROIC ACID .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15936818.001).
  • [ISSN] 0145-2126
  • [Journal-full-title] Leukemia research
  • [ISO-abbreviation] Leuk. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Butyrates; 0 / Enzyme Inhibitors; 0 / Histone Deacetylase Inhibitors; 04079A1RDZ / Cytarabine; 136601-57-5 / Cyclin D1; 147604-94-2 / Cyclin-Dependent Kinase Inhibitor p27; 614OI1Z5WI / Valproic Acid; 6PLQ3CP4P3 / Etoposide
  •  go-up   go-down


5. Matsui K, Tanaka Y, Yamashita K, Matsuda K, Shinohara K: Acute myeloblastic leukemia in a patient with hereditary protein C deficiency. Intern Med; 2006;45(11):729-32
Hazardous Substances Data Bank. CYTARABINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Acute myeloblastic leukemia in a patient with hereditary protein C deficiency.
  • She recently developed acute myeloblastic leukemia (AML).
  • Chemotherapy for AML by cytosine arabinoside, aclarubicin followed by granulocyte colony-stimulating factor (CAG) was started.
  • Disseminated intravascular coagulation (DIC) was observed, however thromboembolic complication was not observed during the hospital course.
  • Hematological remission was not obtained, and the patient died of pseudomembranous pancolitis.
  • Whether the development of these rare disorders of hereditary protein C and AML are coincidental, or involve a causal relationship remains unknown.
  • [MeSH-major] Leukemia, Myeloid, Acute / pathology

  • Genetic Alliance. consumer health - Protein C Deficiency.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16819254.001).
  • [ISSN] 1349-7235
  • [Journal-full-title] Internal medicine (Tokyo, Japan)
  • [ISO-abbreviation] Intern. Med.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 04079A1RDZ / Cytarabine; 143011-72-7 / Granulocyte Colony-Stimulating Factor; 74KXF8I502 / Aclarubicin; CAG protocol
  •  go-up   go-down


6. Kömür M, Erbey F, Bayram I, Tanyeli A: Incidence and prognostic importance of molecular genetic defects in children with acute myeloblastic leukemia. Asian Pac J Cancer Prev; 2010;11(5):1393-5
MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Incidence and prognostic importance of molecular genetic defects in children with acute myeloblastic leukemia.
  • INTRODUCTION: Acute myeloblastic leukemia (AML) accounts for 15 to 25 percent of childhood acute leukemias.
  • The most common genetic abnormalities seen in pediatric AML patients are AML1-ETO, PML-RARα and CBFB-MYH11 genes resulting in t(8;21), t(15;17) and inv(16).
  • These genetic defects are seen in approximately 20-25% of AML patients.
  • OBJECTIVE: We investigated in this study, incidence and prognostic significance of the AML1-ETO, PML-RARα and CBFB-MYH11 genes in children with AML.
  • MATERIALS AND METHODS: The authors analyzed 34 children with AML using the real time-polymerase chain reaction for AML1-ETO, PML-RARα and CBFB-MYH11 genes.
  • CONCLUSION: It was concluded that t(15;17), t(8;21) and inv(16) impact on disease prognosis positively, but comprehensive studies with larger patient series are now needed for confirmation.
  • [MeSH-major] Leukemia, Myeloid, Acute / genetics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21198299.001).
  • [ISSN] 2476-762X
  • [Journal-full-title] Asian Pacific journal of cancer prevention : APJCP
  • [ISO-abbreviation] Asian Pac. J. Cancer Prev.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Thailand
  • [Chemical-registry-number] 0 / AML1-ETO fusion protein, human; 0 / CBFbeta-MYH11 fusion protein; 0 / Core Binding Factor Alpha 2 Subunit; 0 / Oncogene Proteins, Fusion; 0 / promyelocytic leukemia-retinoic acid receptor alpha fusion oncoprotein
  •  go-up   go-down


7. Pulte D, Gondos A, Brenner H: Improvements in survival of adults diagnosed with acute myeloblastic leukemia in the early 21st century. Haematologica; 2008 Apr;93(4):594-600
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Improvements in survival of adults diagnosed with acute myeloblastic leukemia in the early 21st century.
  • Treatment of adults with acute myeloblastic leukemia has changed substantially over the past two decades.
  • Currently available estimates of survival do not reflect results from present state-of-the-art treatment due to a lag between the availability of new treatments and data concerning their effect on survival on the population level when traditional cohort analysis is used.
  • We estimated trends in age-specific 5- and 10-year relative survival of acute myeloblastic leukemia patients aged over 15 years old for 5-year calendar periods from 1980-1984 through 2000-2004 using data from the Surveillance, Epidemiology, and End Results Program.
  • Our period analysis reveals major improvement on the population level in long-term prognosis of younger patients with acute myeloblastic leukemia, most likely explained by multiple incremental improvements in care including better and more specific diagnosis, improvements in and extension of the use of stem cell transplantation and high dose therapy, and improved supportive care.
  • [MeSH-major] Leukemia, Myeloid, Acute / mortality
  • [MeSH-minor] Adolescent. Adult. Age Factors. Aged. Aged, 80 and over. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cohort Studies. Combined Modality Therapy. Disease Management. Female. Hematopoietic Stem Cell Transplantation. Humans. Male. Medical Oncology / methods. Medical Oncology / trends. Middle Aged. Mortality / trends. Prognosis. SEER Program / statistics & numerical data. Survival Analysis. United States / epidemiology

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18322250.001).
  • [ISSN] 1592-8721
  • [Journal-full-title] Haematologica
  • [ISO-abbreviation] Haematologica
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] Italy
  •  go-up   go-down


8. De Braekeleer E, Ianotto JC, Douet-Guilbert N, Meyer C, Morel F, Le Bris MJ, Marschalek R, Berthou C, Férec C, De Braekeleer M: A second case of secondary acute myeloblastic leukemia associated with the MLL-KIAA0284 fusion gene. Blood Cells Mol Dis; 2009 May-Jun;42(3):292-3
Hazardous Substances Data Bank. DAUNORUBICIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A second case of secondary acute myeloblastic leukemia associated with the MLL-KIAA0284 fusion gene.
  • [MeSH-major] Chromosomes, Human, Pair 11 / genetics. Chromosomes, Human, Pair 14 / genetics. Leukemia, Myeloid, Acute / genetics. Neoplasms, Second Primary / genetics. Oncogene Proteins, Fusion / genetics
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / adverse effects. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Base Sequence. Carcinoma, Transitional Cell / drug therapy. Carcinoma, Transitional Cell / radiotherapy. Carcinoma, Transitional Cell / surgery. Chemotherapy, Adjuvant / adverse effects. Chromosome Breakage. Cisplatin / administration & dosage. Cisplatin / adverse effects. Combined Modality Therapy. Cytarabine / administration & dosage. Daunorubicin / administration & dosage. Deoxycytidine / administration & dosage. Deoxycytidine / adverse effects. Deoxycytidine / analogs & derivatives. Fatal Outcome. Humans. Male. Middle Aged. Molecular Sequence Data. Neoplasms, Radiation-Induced / genetics. Nephrectomy. Radiotherapy, Adjuvant / adverse effects. Urologic Neoplasms / drug therapy. Urologic Neoplasms / radiotherapy. Urologic Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19254855.001).
  • [ISSN] 1096-0961
  • [Journal-full-title] Blood cells, molecules & diseases
  • [ISO-abbreviation] Blood Cells Mol. Dis.
  • [Language] eng
  • [Publication-type] Case Reports; Letter; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / MLL-KIAA0284 fusion protein, human; 0 / Oncogene Proteins, Fusion; 04079A1RDZ / Cytarabine; 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine; Q20Q21Q62J / Cisplatin; ZS7284E0ZP / Daunorubicin
  •  go-up   go-down


9. Suga K, Kawakami Y, Hiyama A, Takeda K, Tanizawa Y, Matsunaga N: F-18 FDG PET/CT findings in a case of gastric relapse of acute myeloblastic leukemia. Clin Nucl Med; 2009 Nov;34(11):788-90
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] F-18 FDG PET/CT findings in a case of gastric relapse of acute myeloblastic leukemia.
  • [MeSH-major] Fluorodeoxyglucose F18. Leukemia, Myeloid, Acute / radionuclide imaging. Positron-Emission Tomography. Stomach Neoplasms / prevention & control. Stomach Neoplasms / radionuclide imaging. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • MedlinePlus Health Information. consumer health - CT Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19851176.001).
  • [ISSN] 1536-0229
  • [Journal-full-title] Clinical nuclear medicine
  • [ISO-abbreviation] Clin Nucl Med
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


10. Rüping MJ, Vehreschild JJ, Cornely OA: Primary antifungal prophylaxis in acute myeloblastic leukemia and myelodysplastic syndrome--still an open question? Leuk Lymphoma; 2010 Jan;51(1):20-6
Hazardous Substances Data Bank. CASPOFUNGIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary antifungal prophylaxis in acute myeloblastic leukemia and myelodysplastic syndrome--still an open question?
  • In this review, we aim to compare different early treatment strategies of invasive fungal diseases in patients undergoing induction chemotherapy for acute myelogenous leukemia or myelodysplastic syndrome.
  • In addition to antifungal prophylaxis, empiric treatment with caspofungin or L-AmB may be administered to patients with fever resistant to broad-spectrum antibiotic treatment and without radiographic findings typical of invasive fungal disease.
  • [MeSH-major] Antifungal Agents / therapeutic use. Leukemia, Myeloid, Acute / complications. Mycoses / complications. Mycoses / drug therapy. Myelodysplastic Syndromes / complications
  • [MeSH-minor] Amphotericin B / therapeutic use. Anti-Bacterial Agents / therapeutic use. Clinical Trials as Topic. Drug Resistance, Fungal. Echinocandins / therapeutic use. Fever / drug therapy. Humans. Medical Oncology / methods. Triazoles / therapeutic use

  • Genetic Alliance. consumer health - Myelodysplastic syndromes.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • MedlinePlus Health Information. consumer health - Fungal Infections.
  • MedlinePlus Health Information. consumer health - Myelodysplastic Syndromes.
  • Hazardous Substances Data Bank. AMPHOTERICIN B .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Leuk Lymphoma. 2011 Feb;52(2):339-40 [21281242.001]
  • (PMID = 20017598.001).
  • [ISSN] 1029-2403
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Anti-Bacterial Agents; 0 / Antifungal Agents; 0 / Echinocandins; 0 / Triazoles; 0 / liposomal amphotericin B; 6TK1G07BHZ / posaconazole; 7XU7A7DROE / Amphotericin B; F0XDI6ZL63 / caspofungin
  • [Number-of-references] 51
  •  go-up   go-down


11. Majeed F, Jadko S, Freedman MH, Dror Y: Mutation analysis of SBDS in pediatric acute myeloblastic leukemia. Pediatr Blood Cancer; 2005 Dec;45(7):920-4
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mutation analysis of SBDS in pediatric acute myeloblastic leukemia.
  • BACKGROUND: Shwachman-Diamond syndrome (SDS) is associated with a high risk of myelodysplasia, acute myeloid leukemia (AML), and chromosome 7 abnormalities.
  • Herein, we studied the role of genetic alterations in SBDS in AML.
  • PROCEDURE: DNA was extracted from marrows of SDS patients with AML, as well as from children with de novo AML.
  • To study whether SBDS heterozygosity confers a risk for MDS/AML, data on family members of SDS patients on the Canadian Inherited Marrow Failure Registry (CIMFR) was analyzed.
  • RESULTS: Of two SDS patients with SDS/AML one was homozygous 258 + 2T > C, and one was compound heterozygous 183-184TA > CT/258 + 2T > C.
  • To determine whether a subset of patients with SDS can present with AML, we analyzed 48 AML samples at remission, but no mutations were identified.
  • To address whether acquired mutated SBDS gene is associated with leukemic transformation in de novo AML, we analyzed 77 AML samples at diagnosis or relapse (4 with -7 and 7q-) for SBDS mutations; no alterations were detected.
  • Also, among the relatives of an SDS patient cohort on the registry no cases of MDS/AML were reported.
  • CONCLUSIONS: Common mutations occurred in our SDS patients who develop AML, and thus, AML is not confined to a rare genetic subgroup of SDS.
  • Newly diagnosed patients with AML are unlikely to have an underlying undiagnosed SDS.
  • Acquired SBDS gene mutations also would appear unlikely to play a mechanistic role in de novo AML, and might not be involved in the pathogenesis of chromosome 7 abnormalities as well.
  • [MeSH-major] Chromosome Aberrations. Chromosomes, Human, Pair 7 / genetics. Exons. Leukemia, Myeloid, Acute / genetics. Point Mutation. Proteins / genetics
  • [MeSH-minor] Bone Marrow Diseases / complications. Bone Marrow Diseases / genetics. Case-Control Studies. Child. Child, Preschool. Cohort Studies. DNA Mutational Analysis. Exocrine Pancreatic Insufficiency / complications. Exocrine Pancreatic Insufficiency / genetics. Heterozygote. Humans. Male. Osteochondrodysplasias / complications. Osteochondrodysplasias / genetics. Syndrome

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2005 Wiley-Liss, Inc.
  • (PMID = 16007594.001).
  • [ISSN] 1545-5009
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Proteins; 0 / SBDS protein, human
  •  go-up   go-down


12. Glaser M, Lanisnik B, Gornik-Kramberger K: Aspergillus rhinosinusitis with ethmoid cell involvement in a patient with acute myeloblastic leukemia. Wien Klin Wochenschr; 2005 Jun;117(11-12):392
Hazardous Substances Data Bank. AMPHOTERICIN B .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Aspergillus rhinosinusitis with ethmoid cell involvement in a patient with acute myeloblastic leukemia.
  • [MeSH-major] Ethmoid Sinusitis / diagnosis. Leukemia, Myeloid, Acute / immunology. Maxillary Sinusitis / diagnosis. Opportunistic Infections / diagnosis. Rhinitis / diagnosis
  • [MeSH-minor] Amphotericin B / therapeutic use. Combined Modality Therapy. Endoscopy. Ethmoid Sinus / microbiology. Ethmoid Sinus / pathology. Ethmoid Sinus / surgery. Female. Humans. Middle Aged. Nasal Mucosa / pathology. Orbital Diseases / diagnosis. Orbital Diseases / drug therapy. Orbital Diseases / pathology. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16053193.001).
  • [ISSN] 0043-5325
  • [Journal-full-title] Wiener klinische Wochenschrift
  • [ISO-abbreviation] Wien. Klin. Wochenschr.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Austria
  • [Chemical-registry-number] 7XU7A7DROE / Amphotericin B
  •  go-up   go-down


13. Disel U, Paydas S, Yavuz S, Tuncer I, Alpay R: Bilateral ear Sweet's syndrome in a case with relapse acute myeloblastic leukemia. Leuk Res; 2006 Mar;30(3):364
Hazardous Substances Data Bank. METHYLPREDNISOLONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bilateral ear Sweet's syndrome in a case with relapse acute myeloblastic leukemia.
  • [MeSH-major] Ear, External / pathology. Leukemia, Myeloid, Acute / drug therapy. Sweet Syndrome / drug therapy

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • Hazardous Substances Data Bank. Filgrastim .
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. VIDARABINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Leuk Res. 2006 Nov;30(11):1466-8 [16540169.001]
  • (PMID = 16157374.001).
  • [ISSN] 0145-2126
  • [Journal-full-title] Leukemia research
  • [ISO-abbreviation] Leuk. Res.
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Anti-Inflammatory Agents; 0 / Recombinant Proteins; 04079A1RDZ / Cytarabine; 143011-72-7 / Granulocyte Colony-Stimulating Factor; FA2DM6879K / Vidarabine; PVI5M0M1GW / Filgrastim; X4W7ZR7023 / Methylprednisolone; ZRP63D75JW / Idarubicin; Ida-FLAG protocol
  •  go-up   go-down


14. Fey M, Dreyling M, ESMO Guidelines Working Group: Acute myeloblastic leukemia in adult patients: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol; 2009 May;20 Suppl 4:100-1
MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Acute myeloblastic leukemia in adult patients: ESMO clinical recommendations for diagnosis, treatment and follow-up.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19454422.001).
  • [ISSN] 1569-8041
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 6
  •  go-up   go-down


15. Fey M, Dreyling M, ESMO Guidelines Working Group: Acute myeloblastic leukemia in adult patients: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol; 2008 May;19 Suppl 2:ii58-9
MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Acute myeloblastic leukemia in adult patients: ESMO clinical recommendations for diagnosis, treatment and follow-up.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18456770.001).
  • [ISSN] 1569-8041
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Journal Article; Practice Guideline
  • [Publication-country] England
  •  go-up   go-down


16. ESMO Guidelines Working Group, Fey M: Acute myeloblastic leukemia in adult patients: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol; 2007 Apr;18 Suppl 2:ii47-8
MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Acute myeloblastic leukemia in adult patients: ESMO clinical recommendations for diagnosis, treatment and follow-up.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Ann Oncol. 2008 May;19(5):1027-9
  • (PMID = 17491043.001).
  • [ISSN] 0923-7534
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Journal Article; Practice Guideline
  • [Publication-country] England
  •  go-up   go-down


17. Petit A, Radford I, Waill MC, Romana S, Berger R: NUP98-NSD1 fusion by insertion in acute myeloblastic leukemia. Cancer Genet Cytogenet; 2008 Jan 1;180(1):43-6
MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] NUP98-NSD1 fusion by insertion in acute myeloblastic leukemia.
  • A case of NUP98-NSD1 gene fusion resulting from the insertion of a subtelomeric part of chromosome 11p15.4 within the subtelomeric part of 5q35 was detected in a child with acute myeloblastic leukemia.
  • [MeSH-major] Chromosomes, Human, Pair 11. Chromosomes, Human, Pair 5. Gene Fusion. Leukemia, Myeloid, Acute / genetics. Oncogene Proteins, Fusion / genetics. Translocation, Genetic

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18068532.001).
  • [ISSN] 0165-4608
  • [Journal-full-title] Cancer genetics and cytogenetics
  • [ISO-abbreviation] Cancer Genet. Cytogenet.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / NUP98-NSD1 protein, human; 0 / Oncogene Proteins, Fusion
  •  go-up   go-down


18. Robin M, Schlageter MH, Chomienne C, Padua RA: Targeted immunotherapy in acute myeloblastic leukemia: from animals to humans. Cancer Immunol Immunother; 2005 Oct;54(10):933-43
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Targeted immunotherapy in acute myeloblastic leukemia: from animals to humans.
  • Immunity against acute myeloid leukemia (AML) is demonstrated in humans by the graft-versus-leukemia effect in allogeneic hematopoietic stem cell transplantation.
  • However, due to the fact that leukemic blasts develop various escape mechanisms, antileukemic specific immunity is not able to control leukemic cell proliferation.
  • The aim of immunotherapy is to overcome tolerance and boost immunity to elicit an efficient immune response against leukemia.
  • We review different immunotherapy strategies tested in preclinical animal models of AML and the human trials that spurred from encouraging results obtained in animal models, demonstrate the feasibility of immunotherapy in AML patients.
  • [MeSH-major] Immunotherapy. Leukemia, Myeloid, Acute / therapy

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15889256.001).
  • [ISSN] 0340-7004
  • [Journal-full-title] Cancer immunology, immunotherapy : CII
  • [ISO-abbreviation] Cancer Immunol. Immunother.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Vaccines, DNA
  • [Number-of-references] 115
  •  go-up   go-down


19. Shepard RC, Talluto CC, Jacob G: Phase I study results of nanomolecular liposomal annamycin in refractory ALL. J Clin Oncol; 2009 May 20;27(15_suppl):7066

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • : 7066 Background: There continues to be no effective second-line therapy for refractory AML or ALL and the cure rate with current therapy has not significantly improved in decades.
  • The first-line therapy for adult AML has remained the same 7 + 3 that it was a generation ago.
  • The MTD was determined to be 150 mg/m2/day for 3 days.
  • We are now testing it in a phase I study in children and young adults with refractory ALL or AML.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961442.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


20. Yildirim I, Uçkan D, Cetin M, Tuncer M, Tezcan I: Isolated testicular and bone relapse in children with acute myeloblastic leukemia and chronic graft versus host disease after allogeneic BMT. Turk J Pediatr; 2007 Apr-Jun;49(2):206-9
MedlinePlus Health Information. consumer health - Bone Marrow Transplantation.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Isolated testicular and bone relapse in children with acute myeloblastic leukemia and chronic graft versus host disease after allogeneic BMT.
  • Isolated extramedullary relapse after allogeneic bone marrow transplantation (BMT) for acute myeloblastic leukemia (AML) is very unusual, particularly in patients with graft versus host disease (GVHD) known to be associated with decreased incidence of leukemic relapses.
  • Here we report two unusual post-transplant cases with AML: the first developed testicular relapse during the treatment of chronic GVHD (cGVHD) and bronchiolitis obliterans and the second relapsed as granulocytic sarcoma in the proximal tibia two years after BMT.
  • [MeSH-major] Bone Marrow Transplantation. Graft vs Host Disease / pathology. Leukemia, Myeloid, Acute / pathology. Leukemia, Myeloid, Acute / therapy
  • [MeSH-minor] Adolescent. Bone Neoplasms / secondary. Chronic Disease. Fatal Outcome. Female. Humans. Male. Testicular Neoplasms / secondary

  • Genetic Alliance. consumer health - Chronic Graft versus Host Disease.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17907524.001).
  • [ISSN] 0041-4301
  • [Journal-full-title] The Turkish journal of pediatrics
  • [ISO-abbreviation] Turk. J. Pediatr.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Turkey
  •  go-up   go-down


21. Carré M, Cahn JY: [Should we treat patients over 65 years with acute myeloblastic leukemia?]. Rev Prat; 2010 Dec 20;60(10):1423-6
MedlinePlus Health Information. consumer health - Cancer Chemotherapy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Should we treat patients over 65 years with acute myeloblastic leukemia?].
  • [Transliterated title] Traiter ou non un patient de plus de 65 ans ayant une leucémie aiguë myéloblastique?
  • The incidence of acute myeloblastic leukemia increases with age.
  • The unfavorable biology of the disease, comorbidities, and significant side effects of the intensive treatment make treatment decisions difficult.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Decision Making. Leukemia, Myeloid, Acute / therapy

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21425545.001).
  • [ISSN] 0035-2640
  • [Journal-full-title] La Revue du praticien
  • [ISO-abbreviation] Rev Prat
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


22. Santos FP, Qiao W, Cortes JE, Jones D, Ravandi F, Verma D, Kantarjian H, Borthakur G: Prognostic value of FLT3 mutations among different cytogenetic subgroups in acute myeloid leukemia (AML). J Clin Oncol; 2009 May 20;27(15_suppl):7015

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic value of FLT3 mutations among different cytogenetic subgroups in acute myeloid leukemia (AML).
  • : 7015 Background: Mutations of the FLT3 gene (in special internal tandem duplication -ITD) are common in normal karyotype AML (NK-AML) and are associated with shorter relapse free and overall survival (OS).
  • METHODS: The records of patients (pts) with newly diagnosed AML (from 2003 to 2007) were reviewed.
  • A Cox model was fit for OS, and non-significant variables were eliminated in a step-down fashion with a p- value cut-off of p = .10.
  • No difference was found in median OS between FLT3-mutated and FLT3- wild type pts in the good risk group (not reached (NR) vs NR, P = 0.57) nor in the poor risk group (55 vs 24 weeks, P = 0.44).
  • In intermediate risk, OS was worse in FLT3-ITD positive pts (33 vs 89 weeks, P < 0.0001) but not in FLT3-TKD positive pts (77 vs 70 weeks, P = 0.89).
  • CONCLUSIONS: In our cohort of pts, FLT3 mutations did not have a prognostic impact in AML with good and poor risk karyotype.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961388.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


23. Vey N, Bourhis J, Dombret H, Bordessoule D, Prebet T, Charbonnier A, Squiban P, Damholt B, Blaise D, Olive D: A phase I study of the anti-natural killer inhibitory receptor (KIR) monoclonal antibody (1-7F9, IPH2101) in elderly patients with acute myeloid leukemia (AML). J Clin Oncol; 2009 May 20;27(15_suppl):3015

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase I study of the anti-natural killer inhibitory receptor (KIR) monoclonal antibody (1-7F9, IPH2101) in elderly patients with acute myeloid leukemia (AML).
  • : 3015 Background: The outcome of the majority of patients with AML remains poor, especially in the oldest patients.
  • Allogeneic SCT is a curative approach for AML.
  • In some models, it has been shown that KIR mismatch is important for the anti-leukemic effect of the graft, most probably through unleashed NK cells towards AML blasts, as suggested by enhanced in vitro NK lytic activity of KIR-HLA mismatched donor NK against recipient blasts.
  • We present the results of the first-in-human phase I trial of this agent in patients with AML in complete remission (CR).
  • METHODS: Patients aged 60-80 years with non promyelocytic AML in first CR following induction and 1-6 cycles of consolidation chemotherapy, normal renal, and hepatic functions, KIR-expression on patient NK-cells and who signed informed consent were eligible.Dose escalation (0.0003, 0.003, 0.015, 0.075, 0.3, 1, 3 mg/kg) was studied using a 3+3 scheme.
  • As expected for an IgG4, NK cell numbers were unaffected by the treatment.
  • Upregulation of CD69 on NK cells and concomitant increases in TNF and MIP1b circulating cytokines were observed in some patients at the highest doses (0.075, 0.1, 0.3 mg/kg) but a dose dependency has not been reached yet.
  • At the 0.3mg/kg dose, MTD has not been reached, but a one week receptor blockade and signs of NK activation were observed.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962059.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


24. Maris MB, Ravandi F, Stuart R, Stone R, Cripe L, Cooper M, Strickland S, Turturro F, Stock W, Berman C: A phase II study of voreloxin as single agent therapy for elderly patients (pts) with newly diagnosed acute myeloid leukemia (AML). J Clin Oncol; 2009 May 20;27(15_suppl):7048

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase II study of voreloxin as single agent therapy for elderly patients (pts) with newly diagnosed acute myeloid leukemia (AML).
  • Interim results of REVEAL-1, a phase II study of single agent voreloxin in newly diagnosed elderly AML pts, are reported.
  • Eligibility: newly diagnosed AML (de novo or secondary AML), pts age ≥ 60 and ≥ 1 additional adverse risk factor (age ≥ 70, secondary AML, intermediate or unfavorable cytogenetics, or PS 2).
  • Median duration of remission has not been reached.
  • Voreloxin PK were similar to those in an earlier single agent phase I study in relapsed/refractory AML.
  • Ex-vivo sensitivity did not predict clinical response.
  • CONCLUSIONS: In REVEAL-1, voreloxin demonstrates clinical activity with 2 dosing schedules in previously untreated elderly (age ≥ 60) patients with AML who are unlikely to benefit from standard chemotherapy.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961427.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


25. Basa J, Wolska-Smoleń T, Walter Z, Skotnicki AB: [Granulocytic sarcoma with late transformation into acute myeloblastic leukemia--case report]. Przegl Lek; 2006;63(8):706-10
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Granulocytic sarcoma with late transformation into acute myeloblastic leukemia--case report].
  • Case presentation of a 28-year-old patient with acute myeloblastic leukemia (FAB AML-M4), who underwent surgery of an inguinal tumor a year before the diagnosis of leukemia was made.
  • In retrospective assessment a diagnosis of granulocytic sarcoma was made.
  • [MeSH-major] Brain Neoplasms / secondary. Leukemia, Myeloid, Acute / diagnosis. Leukemia, Myeloid, Acute / etiology. Sarcoma, Myeloid / complications. Sarcoma, Myeloid / diagnosis
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bone Marrow Transplantation. Cell Transformation, Neoplastic / pathology. Disease-Free Survival. Fatal Outcome. Groin. Humans. Male. Neoplasm Recurrence, Local / diagnosis. Remission Induction / methods. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17441389.001).
  • [ISSN] 0033-2240
  • [Journal-full-title] Przegla̧d lekarski
  • [ISO-abbreviation] Prz. Lek.
  • [Language] pol
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Poland
  •  go-up   go-down


26. Gupta A, Singh M, Singh H, Kumar L, Sharma A, Bakhshi S, Raina V, Thulkar S: Febrile neutropenia during acute myeloid leukemia therapy: Single institution experience from a developing country. J Clin Oncol; 2009 May 20;27(15_suppl):e18000

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Febrile neutropenia during acute myeloid leukemia therapy: Single institution experience from a developing country.
  • : e18000 Background: Febrile neutropenia poses a major challenge during treatment of acute myeloid leukaemia (AML).
  • METHODS: Episodes of febrile neutropenia in 104 consecutive patients of AML admitted to the medical oncology ward between May 2001 and December 2006 were studied.
  • RESULTS: 402 febrile episodes including 363 episodes of febrile neutropenia (180 in induction, 183 in consolidation) and 39 non-neutropenic episodes (18 in induction, 21 in consolidation) occurred.
  • Prompt and proper institution of antibiotics and antifungals besides considering alternative diagnosis peculiar to the region (e.g. tuberculosis, malaria) may aid in better management.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964014.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


27. Olcay L, Aribaş BK, Gökçe M: A patient with acute myeloblastic leukemia who presented with conus medullaris syndrome and review of the literature. J Pediatr Hematol Oncol; 2009 Jun;31(6):440-7
MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A patient with acute myeloblastic leukemia who presented with conus medullaris syndrome and review of the literature.
  • In childhood, the conus medullaris syndrome owing to leukemia is rare.
  • Here, a 12-year-old boy with acute myeloblastic leukemia, maxillary mass, and conus medullaris syndrome is reported.
  • A biopsy from the maxillary mass revealed "granulocytic sarcoma."
  • [MeSH-major] Leukemia, Myeloid, Acute / complications. Spinal Cord Compression / etiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19648794.001).
  • [ISSN] 1536-3678
  • [Journal-full-title] Journal of pediatric hematology/oncology
  • [ISO-abbreviation] J. Pediatr. Hematol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Antineoplastic Agents; 0 / Biomarkers, Tumor
  • [Number-of-references] 34
  •  go-up   go-down


28. Olcay L, Dingil G, Yildirim E, Dilek G, Dirim E: Splenic abscesses in therapy-resistant acute myeloblastic leukemia presenting as recurrent febrile neutropenia and unresolved splenomegaly. Turk J Pediatr; 2007 Jul-Sep;49(3):315-8
MedlinePlus Health Information. consumer health - Spleen Diseases.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Splenic abscesses in therapy-resistant acute myeloblastic leukemia presenting as recurrent febrile neutropenia and unresolved splenomegaly.
  • A 14 7/12-year-old boy with acute myeloblastic leukemia M3v was admitted with disseminated intravascular coagulation, otitis media, lobar pneumonia, and splenomegaly.
  • After induction therapy, M2 bone marrow was attained but splenomegaly persisted.
  • Abdominal ultrasonography, which revealed diffuse splenomegaly at admission, showed splenic nodular lesions at the end of the induction therapy.
  • The lesions persisted after M1 bone marrow was attained.
  • He developed acute appendicitis and was operated.
  • The pathologic examination confirmed the diagnosis.
  • He did not have an appropriate bone marrow donor, and developed bone marrow relapse and died.
  • [MeSH-major] Abscess / complications. Leukemia, Myeloid, Acute / complications. Neutropenia / diagnosis. Splenic Diseases / complications
  • [MeSH-minor] Adolescent. Diagnosis, Differential. Fatal Outcome. Humans. Male. Splenomegaly

  • Genetic Alliance. consumer health - Splenomegaly.
  • MedlinePlus Health Information. consumer health - Abscess.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17990589.001).
  • [ISSN] 0041-4301
  • [Journal-full-title] The Turkish journal of pediatrics
  • [ISO-abbreviation] Turk. J. Pediatr.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Turkey
  •  go-up   go-down


29. Pamuk GE, Taşçi M, Oztürk E, Demir M: Successful treatment of severe gastrointestinal bleeding after chemotherapy in acute myeloblastic leukemia with recombinant activated factor VII : report on one case and review of other uses in acute leukemias. Med Oncol; 2010 Mar;27(1):16-9
Hazardous Substances Data Bank. CYTARABINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Successful treatment of severe gastrointestinal bleeding after chemotherapy in acute myeloblastic leukemia with recombinant activated factor VII : report on one case and review of other uses in acute leukemias.
  • Hemorrhage is a frequent complication in patients with acute leukemias as a result of chemotherapy-induced myelosuppression.
  • Patients are generally managed with red blood cell, platelet suspensions, and fresh frozen plasma; and sometimes with pharmacologic and endoscopic interventions.
  • We present our 44-year-old female patient who had gastrointestinal system bleeding after remission induction therapy for acute myeloid leukemia.
  • Thrombocytopenia was refractory to apheresis platelets; and gastrointestinal bleeding could be controlled only after the administration of a single dose (35 microg/kg, total dose 2.4 mg) of rFVIIa.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / adverse effects. Factor VIIa / administration & dosage. Gastrointestinal Hemorrhage / drug therapy. Leukemia, Myeloid, Acute / drug therapy. Recombinant Proteins / administration & dosage

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • MedlinePlus Health Information. consumer health - Gastrointestinal Bleeding.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood Coagul Fibrinolysis. 2004 Apr;15(3):261-3 [15060424.001]
  • [Cites] Bone Marrow Transplant. 2007 Jun;39(12 ):729-35 [17417659.001]
  • [Cites] Semin Thromb Hemost. 2000;26(4):413-9 [11092217.001]
  • [Cites] Am J Hematol. 2005 Aug;79(4):344-5 [16044447.001]
  • [Cites] Gastroenterol Clin North Am. 2003 Dec;32(4):1053-78 [14696297.001]
  • [Cites] Bone Marrow Transplant. 2001 Aug;28(4):405-7 [11571515.001]
  • [Cites] Pediatr Blood Cancer. 2008 May;50(5):1013-7 [17960639.001]
  • [Cites] Arch Intern Med. 2000 Jul 24;160(14 ):2216-7 [10904466.001]
  • [Cites] Blood Coagul Fibrinolysis. 2005 Mar;16(2):145-7 [15741803.001]
  • [Cites] Br J Haematol. 2002 Jun;117(3):705-8 [12028045.001]
  • [Cites] Eur J Haematol. 2004 Jun;72 (6):455-6 [15128428.001]
  • [Cites] Gut. 2002 Oct;51 Suppl 4:iv1-6 [12208839.001]
  • [Cites] Blood Coagul Fibrinolysis. 2006 Jun;17(4):323-4 [16651877.001]
  • [Cites] Am J Gastroenterol. 1995 Apr;90(4):568-73 [7717312.001]
  • [Cites] Blood Coagul Fibrinolysis. 1998 Mar;9 Suppl 1:S61-5 [9819030.001]
  • [Cites] Haemostasis. 1996;26 Suppl 1:159-64 [8904193.001]
  • [Cites] Blood Coagul Fibrinolysis. 1998 Mar;9 Suppl 1:S15-20 [9819024.001]
  • [Cites] J Thromb Haemost. 2003 Mar;1(3):606-8 [12871480.001]
  • [Cites] BMJ. 2001 Nov 10;323(7321):1115-7 [11701581.001]
  • [Cites] Clin Lab Haematol. 2004 Jun;26(3):229-31 [15163323.001]
  • [Cites] Thromb J. 2006 Jan 18;4:1 [16420687.001]
  • [Cites] Eur J Haematol. 2007 Feb;78(2):173-4 [17313564.001]
  • [Cites] Biol Blood Marrow Transplant. 2007 May;13(5):622-3 [17448923.001]
  • [Cites] Am J Hematol. 2006 Sep;81(9):720 [16804937.001]
  • [Cites] Br J Haematol. 1999 Jul;106(1):254-5 [10444198.001]
  • [Cites] Crit Care Med. 2005 Apr;33(4):883-90 [15818119.001]
  • [Cites] Blood Coagul Fibrinolysis. 2000 Apr;11 Suppl 1:S107-11 [10850574.001]
  • [Cites] Haemostasis. 1996;26 Suppl 1:143-9 [8904190.001]
  • [Cites] Pediatr Hematol Oncol. 2006 Jun;23 (4):339-45 [16621776.001]
  • [Cites] Bone Marrow Transplant. 2002 Dec;30(12):975-8 [12476294.001]
  • (PMID = 19137431.001).
  • [ISSN] 1559-131X
  • [Journal-full-title] Medical oncology (Northwood, London, England)
  • [ISO-abbreviation] Med. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 0 / Antimetabolites, Antineoplastic; 0 / Recombinant Proteins; 04079A1RDZ / Cytarabine; EC 3.4.21.21 / Factor VIIa; ZRP63D75JW / Idarubicin
  •  go-up   go-down


30. Giles FJ, O'Brien S, Rizzieri DA, Vey N, Krug U, Sekeres M, Jacobsen TF, Nilsson BI, Staudacher K: A phase II study with CP-4055 in patients with second salvage AML. J Clin Oncol; 2009 May 20;27(15_suppl):7047

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase II study with CP-4055 in patients with second salvage AML.
  • : 7047 Background: CP-4055 (cytarabine 5'-elaidic acid ester) is a novel derivative of cytarabine, independent of nucleoside transporters to enter the cell.
  • The aim of this study was to assess efficacy and safety of CP-4055 when given as second salvage therapy to patients (pts) with acute myeloid leukemia (AML).
  • METHODS: Adult pts who received two previous chemotherapy regimens and who had refractory/relapsed AML (CR after first salvage therapy lasting less than 6 months) were enrolled.
  • 6 pts had previous transplant, the majority of the pts had previous ara-C based therapy, 12 pts had not obtained CR1 or CR2.
  • Only 1 pt did not receive d1-5 dosing.
  • Most frequently reported related AE ≥ grade 3 (CTCAE v3.0) were myelosuppression, abdominal pain, colitis, diarrhoea, nausea, fatigue, liver function test (LFT) elevation.
  • Clinical activity (IWG criteria for AML), 2 CR (1 with no CR1 or CR2), and 1 CRp (CR rate 15%), were reported.
  • CONCLUSIONS: CP-4055 given as second salvage therapy to AML pts show manageable toxicity when administered at 2,000 mg/m<sup>2</sup>/d, 24 h CIV, in a d1-5 q3w schedule.
  • Clinical activity (2 CR and 1 CRp) has been reported among the first 20 late stage AML pts.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961426.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


31. Lyman GH, Dale DC, Culakova E, Poniewierski MS, Wolff D, Kuderer NM, Lambert K, Crawford J: Acute myeloid leukemia or myelodysplastic syndrome (AML/MDS) and overall mortality with chemotherapy (CT) and granulocyte colony-stimulating factor (G-CSF): A meta-analysis of randomized controlled trials (RCTs). J Clin Oncol; 2009 May 20;27(15_suppl):9524

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Acute myeloid leukemia or myelodysplastic syndrome (AML/MDS) and overall mortality with chemotherapy (CT) and granulocyte colony-stimulating factor (G-CSF): A meta-analysis of randomized controlled trials (RCTs).
  • : 9524 Background: To evaluate the risk of AML/MDS and overall mortality in patients receiving CT ± G-CSF, a meta-analysis of RCTs were conducted.
  • Eligibility included RCTs of solid tumor or lymphoma patients randomized to CT ± primary G-CSF support, ≥2 years follow-up and reporting AML/MDS or all second malignancies.
  • Pre-specified study categories included: a)same dose/schedule, b)dose-dense or c)dose-escalated CT.
  • Primary outcomes were AML/MDS and mortality.
  • RR for AML/MDS with CT+G-CSF compared to control was 1.92 [P=.006] with ARD increase of 0.4% [P=.008].
  • RR for AML/MDS in study categories to receive the same, dose-dense or dose-escalated CT+G-CSF were 1.95 [P=.346], 1.20 [P=.666] and 2.47 [P=.006], respectively.
  • No differences in estimates of AML/MDS or mortality were observed between industry and non-industry-funded studies.
  • CONCLUSIONS: Risk of AML/MDS is increased with dose escalated CT+G-CSF.
  • Dose-dense regimens are associated with the greatest RR reduction in mortality and lowest risk of AML/MDS.
  • Further research is needed to differentiate any impact of G-CSF on the risk of AML/MDS from that due to increased CT intensity.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964513.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


32. Wang HF, Cheng YZ, Wang HP, Chen ZM, Lou JY, Jin J: CD19-positive acute myeloblastic leukemia with trisomy 21 as a sole acquired karyotypic abnormality. J Zhejiang Univ Sci B; 2009 Nov;10(11):833-8
MedlinePlus Health Information. consumer health - Down Syndrome.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CD19-positive acute myeloblastic leukemia with trisomy 21 as a sole acquired karyotypic abnormality.
  • We report that a 63-year-old Chinese female had acute myeloblastic leukemia (AML) in which trisomy 21 (+21) was found as the sole acquired karyotypic abnormality.
  • The patient did not have any features of Down syndrome.
  • A diagnosis of CD19-positive AML-M5 was established with trisomy 21 as a sole acquired karyotypic abnormality.
  • The patient did not respond well to chemotherapy and died three months after the diagnosis.
  • This is the first reported case of CD19-positive AML with trisomy 21 as the sole cytogenetic abnormality.
  • The possible prognostic significance of the finding in AML with +21 as the sole acquired karyotypic abnormality was discussed.
  • [MeSH-major] Antigens, CD19 / biosynthesis. Down Syndrome / genetics. Leukemia, Myeloid, Acute / genetics

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Leuk Res. 1999 Nov;23(11):1079-83 [10576514.001]
  • [Cites] Arch Med Res. 2007 Oct;38(7):797-802 [17845902.001]
  • [Cites] Cancer Genet Cytogenet. 2001 May;127(1):77-9 [11408071.001]
  • [Cites] Cancer Genet Cytogenet. 2002 Mar;133(2):183-4 [11943351.001]
  • [Cites] Cancer Genet Cytogenet. 1986 Jun;22(2):99-108 [3708552.001]
  • [Cites] Cancer Genet Cytogenet. 1987 Nov;29(1):9-21 [3478133.001]
  • [Cites] Cancer Genet Cytogenet. 1989 Jul 15;40(2):203-16 [2766244.001]
  • [Cites] J Clin Oncol. 1990 Mar;8(3):423-30 [2307987.001]
  • [Cites] Am J Med Genet Suppl. 1990;7:247-50 [2149957.001]
  • [Cites] Am J Med Genet Suppl. 1990;7:262-6 [2149959.001]
  • [Cites] Blood. 1991 May 15;77(10):2242-50 [1709379.001]
  • [Cites] Leukemia. 1992 Mar;6(3):171-5 [1533007.001]
  • [Cites] Leukemia. 1992 May;6(5):393-9 [1375696.001]
  • [Cites] Blood. 1992 Nov 1;80(9):2210-4 [1384797.001]
  • [Cites] Leukemia. 1993 Apr;7(4):489-98 [7681917.001]
  • [Cites] Blood. 1993 May 1;81(9):2399-405 [7683218.001]
  • [Cites] Baillieres Clin Haematol. 1992 Oct;5(4):815-31 [1308166.001]
  • [Cites] Blood. 1993 Nov 15;82(10):3098-102 [8219201.001]
  • [Cites] Blood. 1994 Aug 15;84(4):1220-5 [8049437.001]
  • [Cites] Leukemia. 1995 Jan;9(1):115-7 [7845005.001]
  • [Cites] Am J Hum Genet. 1995 Apr;56(4):915-25 [7717402.001]
  • [Cites] Cancer Genet Cytogenet. 1996 Feb;86(2):177-80 [8603351.001]
  • [Cites] Cancer Genet Cytogenet. 1997 Jun;95(2):213-4 [9169044.001]
  • [Cites] Am J Hematol. 1998 Aug;58(4):278-84 [9692390.001]
  • [Cites] Lancet. 2000 Jan 15;355(9199):165-9 [10675114.001]
  • (PMID = 19882758.001).
  • [ISSN] 1862-1783
  • [Journal-full-title] Journal of Zhejiang University. Science. B
  • [ISO-abbreviation] J Zhejiang Univ Sci B
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Antigens, CD19; 0 / Antigens, CD34; 0 / Antigens, Differentiation, Myelomonocytic; 0 / CD33 protein, human; 0 / HLA-DR Antigens; 0 / Sialic Acid Binding Ig-like Lectin 3; EC 1.11.1.7 / Peroxidase
  • [Other-IDs] NLM/ PMC2772888
  •  go-up   go-down


33. Ikawa Y, Sugimoto N, Koizumi S, Yachie A, Saikawa Y: Promoter DNA methylation of CD10 in infant acute lymphoblastic leukemia with MLL/AF4 fusion gene. J Clin Oncol; 2009 May 20;27(15_suppl):10045

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Promoter DNA methylation of CD10 in infant acute lymphoblastic leukemia with MLL/AF4 fusion gene.
  • While CD10 negativity reflects an earlier stage of B-cell development, complete IgH gene rearrangements (VDJ<sub>H</sub>) show more mature IgH status.
  • METHODS: CD10-negative infant ALL with MLL/AF4, CD10-positive infant ALL with germ-line MLL, CD10-positive pre-B ALL cell line, infant AML (M5) with MLL/AF9 and pediatric AML (M2) with AML1/ETO were analyzed for VDJ<sub>H</sub> status and methylation of CD10 gene promoters.
  • In contrast, none or a few of the CpG dinucleotides were methylated in the CD10-positive ALL, AML (M5) with MLL/AF9 or AML (M2) with AML1/ETO.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962471.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


34. Cetin Z, Tezcan G, Karauzum SB, Kupesiz A, Manguoglu AE, Yesilipek A, Luleci G, Hazar V: Donor cell-derived acute myeloblastic leukemia after allogeneic peripheral blood hematopoietic stem cell transplantation for juvenile myelomonocytic leukemia. J Pediatr Hematol Oncol; 2006 Nov;28(11):763-7
MedlinePlus Health Information. consumer health - Blood Transfusion and Donation.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Donor cell-derived acute myeloblastic leukemia after allogeneic peripheral blood hematopoietic stem cell transplantation for juvenile myelomonocytic leukemia.
  • Despite its rarity, donor cell leukemia (DCL) is a most intriguing entity.
  • We report here the case of a 5 year-old girl with juvenile myelomonocytic leukemia and normal female karyotype who developed acute myeloblastic leukemia with a karyotype of 46, X, t(X;.
  • q22) 5 months after peripheral blood hematopoietic stem cell transplantation from her HLA-matched sister.
  • This analysis showed that the leukemic blood DNA matched the donor blood DNA and not the patient's DNA, thus confirming DCL.
  • To our knowledge, this is the first case of DCL after peripheral blood SCT for juvenile myelomonocytic leukemia.
  • [MeSH-major] Blood Donors. Leukemia, Myeloid, Acute / etiology. Leukemia, Myelomonocytic, Chronic / therapy. Peripheral Blood Stem Cell Transplantation / adverse effects. Transplantation Chimera


35. Schwind S, Marcucci G, Maharry K, Radmacher MD, Whitman SP, Paschka P, Mrózek K, Kolitz JE, Larson RA, Bloomfield CD, Cancer and Leukemia Group B (CALGB): MicroRNA 181a (miR-181a) expression as a prognosticator in cytogenetically normal acute myeloid leukemia (CN AML). J Clin Oncol; 2009 May 20;27(15_suppl):7001

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] MicroRNA 181a (miR-181a) expression as a prognosticator in cytogenetically normal acute myeloid leukemia (CN AML).
  • : 7001 Background: We showed recently that CEBPA mutations (mut) in CN AML are associated with better outcome and a unique microRNA expression profile, including miR-181a upregulation.
  • METHODS: We analyzed 187 de novo CN AML adult patients (pts) aged <60 years (y; median 45) similarly treated on CALGB 9621 and 19808.
  • Of these, 122 had molecular high risk [FLT3-ITD or NPM1 wild type (wt)] and 65 low risk (no FLT3-ITD, NPM1 mut) CN AML.
  • The mean of 2 miR-181a probe log intensities was used as a continuous variable for analyses.
  • RESULTS: Higher miR-181a levels (miR-181a↑) were associated with CEBPA mut, NPM1 wt, no FLT3-TKD, lower ERG expression, higher %FAB M1/M2, lower WBC and age, higher blood blasts, and lower % gum hypertrophy. miR-181a↑ tended to associate with more complete remissions (CRs; p = .07) and significantly associated with longer disease-free (DFS; p = .05) and overall (OS; p = .01) survival (median follow-up 6.5 y for pts alive).
  • CONCLUSIONS: miR-181a expression is a prognostic marker in CN AML, mainly in the molecular high risk group, where it predicts outcome independently of other variables including CEBPA mutations.
  • As miR-181a↑ confer better treatment response, novel approaches increasing miR-181a levels might benefit not only CN but also other AML pts.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961373.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


36. Mashita T, Shimoda T, Yoshioka H, Takahashi Y, Mitsuda M: A cat with acute myeloblastic leukemia without maturation (M1) treated with combination chemotherapy. J Vet Med Sci; 2006 Jan;68(1):97-101
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A cat with acute myeloblastic leukemia without maturation (M1) treated with combination chemotherapy.
  • Hematologic findings revealed a mild non-regenerative anemia, thrombocytopenia, and leukocytosis with an increase in blast cells.
  • Acute myeloblastic leukemia without maturation (M1) was diagnosed according to the FAB classification.

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16462128.001).
  • [ISSN] 0916-7250
  • [Journal-full-title] The Journal of veterinary medical science
  • [ISO-abbreviation] J. Vet. Med. Sci.
  • [Language] ENG
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 04079A1RDZ / Cytarabine; 5J49Q6B70F / Vincristine; 8N3DW7272P / Cyclophosphamide; 9PHQ9Y1OLM / Prednisolone; EC 1.11.1.7 / Peroxidase
  •  go-up   go-down


37. Monzo M, Brunet S, Urbano-Ispizua A, Navarro A, Perea G, Esteve J, Artells R, Granell M, Berlanga J, Ribera JM, Bueno J, Llorente A, Guardia R, Tormo M, Torres P, Nomdedéu JF, Montserrat E, Sierra J, CETLAM: Genomic polymorphisms provide prognostic information in intermediate-risk acute myeloblastic leukemia. Blood; 2006 Jun 15;107(12):4871-9
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Genomic polymorphisms provide prognostic information in intermediate-risk acute myeloblastic leukemia.
  • Current prognostic factors for acute myeloblastic leukemia (AML) are not sufficient to accurately predict the group of patients in the intermediate-risk category who will successfully respond to treatment.
  • We used the allelic discrimination method to identify polymorphisms in GSTT1, SULT1C2, CDA, SXR (drug metabolic pathways), XPD, XPA, XPG, ERCC1, TOP2A (DNA repair), VEGF (angiogenesis), and MDR1 (multidrug resistance) genes in 110 adult patients with intermediate-risk AML, enrolled in the CETLAM-99 prospective trial.
  • A multivariate prognostic model adjusted for age, white blood cell (WBC) count, French-American-British group, cytogenetics, MLL rearrangement, internal tandem duplication of FLT3 (FLT3-ITD), induction courses to achieve complete remission, and germline polymorphisms, was used to detect independent risk factors associated with clinical outcome.
  • These findings might be useful in selecting risk-adapted treatment strategies in intermediate-risk AML.
  • [MeSH-major] Leukemia, Myeloid, Acute / genetics. Leukemia, Myeloid, Acute / mortality. Neoplasm Proteins / genetics. Polymorphism, Genetic
  • [MeSH-minor] Adult. Alleles. Disease-Free Survival. Female. Heterozygote. Humans. Leukocyte Count. Male. Multivariate Analysis. Prognosis. Prospective Studies. Recurrence. Remission Induction. Risk Factors. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16507781.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Neoplasm Proteins
  •  go-up   go-down


38. Meng YS, Khoury H, Dick JE, Minden MD: Oncogenic potential of the transcription factor LYL1 in acute myeloblastic leukemia. Leukemia; 2005 Nov;19(11):1941-7
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Oncogenic potential of the transcription factor LYL1 in acute myeloblastic leukemia.
  • The LYL1 gene encodes a basic helix-loop-helix transcription factor involved in T-cell acute lymphoblastic leukemia.
  • Using real-time quantitative RT-PCR assay, we found that the expression of LYL1 was at higher levels in the majority cases of acute myeloblastic leukemia (AML) or myelodysplastic syndrome when compared to normal bone marrow.
  • Our study also showed that LYL1 was highly expressed in most AML cell lines and in CD34+ AML cells.
  • To determine whether LYL1 had an affect on the phenotype and behavior of myeloid cells, we introduced full-length LYL1 cDNA into K562 cells using electroporation and U937 cells with retroviral infection.
  • Both of the derivative cell lines with overexpression of LYL1 had an increased growth rate and clonogenecity.
  • Forced expression of LYL1 in K562 cells enhanced spontaneous and hemin-induced erythroid differentiation but blocked spontaneous as well as PMA-induced megakaryocytic differentiation.
  • These results demonstrate that LYL1 may play a role in early hematopoiesis and may be a potential oncogenic factor in AML.
  • [MeSH-major] Cell Transformation, Neoplastic / genetics. DNA-Binding Proteins / biosynthesis. DNA-Binding Proteins / genetics. Gene Expression Profiling. Leukemia, Myeloid, Acute / genetics. Neoplasm Proteins / biosynthesis. Neoplasm Proteins / genetics

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. ALL-TRANS-RETINOIC ACID .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16094422.001).
  • [ISSN] 0887-6924
  • [Journal-full-title] Leukemia
  • [ISO-abbreviation] Leukemia
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Antineoplastic Agents, Alkylating; 0 / Basic Helix-Loop-Helix Transcription Factors; 0 / DNA, Complementary; 0 / DNA-Binding Proteins; 0 / LYL1 protein, human; 0 / Neoplasm Proteins; 04079A1RDZ / Cytarabine; 5688UTC01R / Tretinoin
  •  go-up   go-down


39. Memarian A, Jeddi Tehrani M, Vossough P, Sharifian RA, Rabbani H, Shokri F: Expression profile of Wnt molecules in leukemic cells from Iranian patients with acute myeloblastic leukemia. Iran J Immunol; 2007 Sep;4(3):145-54
MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression profile of Wnt molecules in leukemic cells from Iranian patients with acute myeloblastic leukemia.
  • BACKGROUND: Wnt molecules play a key role in growth, proliferation and development of some embryonic and adult organs as well as hematopoietic stem cells.
  • OBJECTIVE: To investigate the expression profile of a large number of Wnt genes in leukemic cells from Iranian patients with acute myeloblastic leukemia.
  • METHODS: RT-PCR method was used to determine the Wnt genes expression in bone marrow (BM) and/or peripheral blood (PB) samples from 16 patients with AML and PB samples of 36 normal subjects.
  • RESULTS: Among 14 Wnt molecules included in this study, Wnt-7A and Wnt-10A were significantly down-regulated (p = 0.002 and p < 0.0001, respectively) and Wnt-3 was significantly over-expressed (p < 0.02) in AML patients compared to normal subjects.
  • No significant association was found between Wnt expression and FAB classification of the patients.
  • CONCLUSION: Our results demonstrated for the first time aberrant expression of Wnt-7A, Wnt-10A and Wnt-3 genes in Iranian AML patients.
  • [MeSH-major] Gene Expression Regulation, Neoplastic. Leukemia, Myeloid, Acute / metabolism. Wnt Proteins / genetics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17767013.001).
  • [ISSN] 1735-1383
  • [Journal-full-title] Iranian journal of immunology : IJI
  • [ISO-abbreviation] Iran J Immunol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Iran
  • [Chemical-registry-number] 0 / Wnt Proteins
  •  go-up   go-down


40. Sierra M, Hernández JM, García JL, Gutiérrez NC, Pérez JJ, Vidriales MB, Ramos F, Hernández JM, Romero M, González MB, Galende J, San Miguel JF: Hematological, immunophenotypic, and cytogenetic characteristics of acute myeloblastic leukemia with trisomy 11. Cancer Genet Cytogenet; 2005 Jul 1;160(1):68-72
MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hematological, immunophenotypic, and cytogenetic characteristics of acute myeloblastic leukemia with trisomy 11.
  • We evaluated the incidence of trisomy 11 in acute myeloblastic leukemia (AML) and its correlation with the most relevant clinical, biological, and immunophenotypic disease characteristics in a total of 399 consecutive AML patients.
  • Trisomy 11 was found in 15 patients (3.8%), in 3 of them as the sole abnormality.
  • [MeSH-major] Chromosomes, Human, Pair 11. Leukemia, Myeloid, Acute / genetics. Trisomy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15949573.001).
  • [ISSN] 0165-4608
  • [Journal-full-title] Cancer genetics and cytogenetics
  • [ISO-abbreviation] Cancer Genet. Cytogenet.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


41. Pulte D, Gondos A, Brenner H: Expected long-term survival of patients diagnosed with acute myeloblastic leukemia during 2006-2010. Ann Oncol; 2010 Feb;21(2):335-41
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expected long-term survival of patients diagnosed with acute myeloblastic leukemia during 2006-2010.
  • BACKGROUND: Treatment of acute myeloblastic leukemia (AML) has evolved over the past several decades.
  • Therefore, currently available estimates of long-term survival, which are based on survival for patients treated with potentially now obsolete protocols, may not pertain to patients currently diagnosed.
  • METHODS: Using data from the 1973-2005 database of the Surveillance, Epidemiology, and End Results Program, we empirically validated a novel model-based method to project 5- and 10-year relative survival of AML patients and we applied the method to project relative survival of AML patients in the United States diagnosed during 2006-2010.
  • CONCLUSION: Patients diagnosed with AML during 2006-2010 at younger ages have much higher long-term survival expectations than indicated by previously available survival statistics.

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19633049.001).
  • [ISSN] 1569-8041
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


42. Stuart RK, Stockerl-Goldstein K, Cooper M, Devetten M, Herzig R, Medeiros B, Schiller G, Wei A, Acton G, Rizzieri D: Randomized phase II trial of the nucleolin targeting aptamer AS1411 combined with high-dose cytarabine in relapsed/refractory acute myeloid leukemia (AML). J Clin Oncol; 2009 May 20;27(15_suppl):7019

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Randomized phase II trial of the nucleolin targeting aptamer AS1411 combined with high-dose cytarabine in relapsed/refractory acute myeloid leukemia (AML).
  • AS1411 has synergistic effects in combination with cytarabine on AML cell lines in vitro and in vivo.
  • METHODS: This open-label randomized phase II trial compared AS1411 plus high-dose cytarabine (HiDAC) with HiDAC alone in patients with primary refractory or relapsed AML who had received up to 3 previous lines of chemotherapy.
  • CONCLUSIONS: Data from this first phase II trial of an aptamer in oncology are encouraging.
  • The combination of AS1411 at 10 or 40 mg/kg/day with HiDAC appears well tolerated and shows promising signs of activity in patients with relapsed/refractory AML.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961391.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


43. Fey MF, Greil R, Jost LM, ESMO Guidelines Task Force: ESMO Minimum Clinical Recommendations for the diagnosis, treatment and follow-up of acute myeloblastic leukemia (AML) in adult patients. Ann Oncol; 2005;16 Suppl 1:i48-9
MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] ESMO Minimum Clinical Recommendations for the diagnosis, treatment and follow-up of acute myeloblastic leukemia (AML) in adult patients.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15888751.001).
  • [ISSN] 0923-7534
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Guideline; Journal Article; Practice Guideline
  • [Publication-country] England
  •  go-up   go-down


44. Blaise DP, Michel Boiron J, Faucher C, Mohty M, Bay JO, Bardoux VJ, Perreau V, Coso D, Pigneux A, Vey N: Reduced intensity conditioning prior to allogeneic stem cell transplantation for patients with acute myeloblastic leukemia as a first-line treatment. Cancer; 2005 Nov 1;104(9):1931-8
MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Reduced intensity conditioning prior to allogeneic stem cell transplantation for patients with acute myeloblastic leukemia as a first-line treatment.
  • BACKGROUND: Thirty-three patients (median age 52; range 26-60) with acute myeloblastic leukemia (AML) were included in a pilot study of allogeneic stem cell transplantation (Allo-SCT) following a reduced-intensity conditioning (RIC).
  • RESULTS: All patients engrafted had cumulative incidences of Gluksberg System Grade 2 acute and chronic graft-versus-host-disease (GVHD) of 24 (9-39%) and 64 (48-80%), respectively.
  • With a median follow-up of 18 months (range 7-52) after Allo-SCT, 26 patients are alive, of whom 24 remained in CR1 for a 2-year overall survival and leukemia-free survival (LFS) probabilities of 79 (range 61-90%) and 76 (range 59-87%), respectively.
  • CONCLUSIONS: We conclude that the sequential combination of intensive chemotherapy and allogeneic immunotherapy might offer relatively low NRD and leukemia relapse rates even in high-risk patients.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Leukemia, Myeloid, Acute / therapy. Stem Cell Transplantation / methods. Transplantation Conditioning / methods

  • Genetic Alliance. consumer health - Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2005 American Cancer Society.
  • (PMID = 16178004.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


45. Derenzini E, Paolini S, Martinelli G, Campidelli C, Grazi GL, Calabrese C, Zinzani PL, Baccarani M: Extramedullary myeloid tumour of the stomach and duodenum presenting without acute myeloblastic leukemia: a diagnostic and therapeutic challenge. Leuk Lymphoma; 2008 Jan;49(1):159-62
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Extramedullary myeloid tumour of the stomach and duodenum presenting without acute myeloblastic leukemia: a diagnostic and therapeutic challenge.
  • [MeSH-major] Sarcoma, Myeloid / diagnosis. Sarcoma, Myeloid / therapy
  • [MeSH-minor] Adult. Combined Modality Therapy. Duodenal Neoplasms / diagnosis. Duodenal Neoplasms / therapy. Humans. Leukemia, Myeloid, Acute. Male. Neoplasm Invasiveness. Remission Induction / methods. Stomach Neoplasms / diagnosis. Stomach Neoplasms / therapy

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18203027.001).
  • [ISSN] 1029-2403
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] England
  •  go-up   go-down


46. Ozyurek E, Alioglu B, Coskun M, Ozbek N: Successful use of short-course high-dose methylprednisolone in a child with acute myeloblastic leukemia (FAB M2) and myeloid tumor. Leuk Lymphoma; 2006 May;47(5):923-5
Hazardous Substances Data Bank. METHYLPREDNISOLONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Successful use of short-course high-dose methylprednisolone in a child with acute myeloblastic leukemia (FAB M2) and myeloid tumor.
  • [MeSH-major] Leukemia, Myeloid, Acute / drug therapy. Methylprednisolone / therapeutic use. Sarcoma, Myeloid / drug therapy

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16753881.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] England
  • [Chemical-registry-number] X4W7ZR7023 / Methylprednisolone
  •  go-up   go-down


47. Altintas A, Ayyildiz O, Isikdogan A, Atay E, Kaplan MA: Successful initial treatment with caspofungin alone for hepatosplenic candidiasis in a patient with acute myeloblastic leukemia. Saudi Med J; 2006 Sep;27(9):1423-4
Hazardous Substances Data Bank. CASPOFUNGIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Successful initial treatment with caspofungin alone for hepatosplenic candidiasis in a patient with acute myeloblastic leukemia.
  • [MeSH-major] Antifungal Agents / therapeutic use. Candidiasis / drug therapy. Leukemia, Myeloid, Acute / complications. Liver Diseases / microbiology. Peptides, Cyclic / therapeutic use. Splenic Diseases / microbiology


48. Yang G, Tang SQ, Huang DS, Wang JW, Liu Y, Wang JY: [Aplastic anemia transformed into acute myeloblastic leukemia M1 8 years later: a case report]. Zhonghua Er Ke Za Zhi; 2005 Mar;43(3):221
MedlinePlus Health Information. consumer health - Aplastic Anemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Aplastic anemia transformed into acute myeloblastic leukemia M1 8 years later: a case report].
  • [MeSH-major] Anemia, Aplastic / complications. Leukemia, Myeloid, Acute / etiology

  • Genetic Alliance. consumer health - Anemia.
  • Genetic Alliance. consumer health - Aplastic Anemia.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15833206.001).
  • [ISSN] 0578-1310
  • [Journal-full-title] Zhonghua er ke za zhi = Chinese journal of pediatrics
  • [ISO-abbreviation] Zhonghua Er Ke Za Zhi
  • [Language] chi
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] China
  •  go-up   go-down


49. Lancet JE, Karp J, Cripe L, Roboz G, Wollman M, Berman C, Conroy A, Hawtin R, Fox J, Michelson G: Phase Ib/II pharmacokinetic/pharmacodynamic (PK/PD) study of combination voreloxin and cytarabine in relapsed or refractory AML patients. J Clin Oncol; 2009 May 20;27(15_suppl):7005

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase Ib/II pharmacokinetic/pharmacodynamic (PK/PD) study of combination voreloxin and cytarabine in relapsed or refractory AML patients.
  • Clinical activity is observed in ovarian cancer and AML.
  • Interim results from a phase Ib/II study in relapsed or refractory AML are reported.
  • METHODS: Dose-escalation in relapsed/refractory AML patients (pts) with ≤ 3 prior induction regimens; phase II expansion in first-relapse pts (CR1 ≥ 3 months) at MTD.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961377.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


50. Slavcheva V, Lukanov T, Tzvetkov N: Two cases of extramedullary myeloid tumor in patients with continuous remission of acute myeloblastic leukemia. J BUON; 2008 Oct-Dec;13(4):589-92
MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Two cases of extramedullary myeloid tumor in patients with continuous remission of acute myeloblastic leukemia.
  • Myeloid sarcoma is described as tumor mass consisting of myeloblasts or immature myeloid cells, involving extramedullary tissues.
  • It can be initial manifestation of myeloproliferative disorders or relapse of previously treated acute myeloblastic leukemia (AML).
  • We present two patients, one with AML-M2 and the other with acute promyelocytic leukemia (APL)-M3.
  • After remission induced by conventional chemotherapy, which continued for 3 and 10 years respectively, a myeloid sarcoma was diagnosed.
  • Biopsy of a retroauricular tumor formation was made in the first case.
  • The second one was diagnozed after biopsy of a supraclavicular lymph node.
  • Two years after the diagnosis of myeloid sarcoma the patient died of haemorrhagic stroke.
  • The patient with AML-M2 continued treatment with polychemotherapy.
  • [MeSH-major] Leukemia, Myeloid, Acute / pathology. Leukemia, Promyelocytic, Acute / pathology. Sarcoma, Myeloid / pathology

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19145688.001).
  • [ISSN] 1107-0625
  • [Journal-full-title] Journal of B.U.ON. : official journal of the Balkan Union of Oncology
  • [ISO-abbreviation] J BUON
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Greece
  •  go-up   go-down


51. Becker H, Marcucci G, Maharry K, Margeson D, Radmacher MD, Whitman SP, Mrózek K, Baer MR, Larson RA, Bloomfield CD, for Cancer and Leukemia Group B (CALGB): NPM1 mutations as an independent prognosticator for older cytogenetically normal acute myeloid leukemia (CN AML). J Clin Oncol; 2009 May 20;27(15_suppl):7000

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] NPM1 mutations as an independent prognosticator for older cytogenetically normal acute myeloid leukemia (CN AML).
  • : 7000 Background: In younger CN AML without FLT3-ITD, NPM1 mutations predict favorable outcome.
  • METHODS: Pretreatment marrow was studied in 189 older CN AML pts [median age 69 y (60 - 83 y); 162 de novo & 27 secondary (s; prior hematologic disorders) cases] enrolled on CALGB 9720 (n=106) & 10201 (n=83).
  • RESULTS: In de novo CN AML, NPM1 mutated (NPM1mut) pts (54%) had more CRs (85% v 45%, P<.0001) & longer relapse-free (RFS) (P=.02; 3 y rates 23% v 10%) & overall survival (OS) (P<.0001; 3 y 34% v 7%) than NPM1 wild-type (NPM1wt) pts.
  • CONCLUSIONS: NPM1 mutations independently predict better outcome in older CN AML.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963957.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


52. Barret J, Dumontet C, Annereau J, Brel V, Breillout F, Guminski Y, Imbert T, Guilbaud N, Bailly C: A functional procedure using fresh samples to select patients with acute myeloid leukemia prior to treatment with the novel targeted cytotoxic agent F14512. J Clin Oncol; 2009 May 20;27(15_suppl):11087

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A functional procedure using fresh samples to select patients with acute myeloid leukemia prior to treatment with the novel targeted cytotoxic agent F14512.
  • This system can be viewed as a suitable molecular gate to deliver selectively polyamine-based molecules into cancer cells.
  • This study was undertaken to investigate the potential of N-methyl-spermine-NBD, a proprietary fluorescent polyamine conjugate, designed to select patients with PTS-positive leukemic cells.
  • METHODS: The uptake of this probe was first measured by flow cytometry in a panel of human leukemia cell lines.
  • RESULTS: Data showed that high level of fluorescence was detected in F14512 -sensitive cancer cell lines whereas leukemia cells responding poorly to F14512 generally exhibited very low levels of PTS.
  • A panel of 50 fresh human acute myeloid leukemia samples showed a larger inter-individual variation and, interestingly, incorporation of the fluorescent probe was generally higher in leukemia blasts than in lymphocytes.
  • CONCLUSIONS: The data show that the PTS can easily be evaluated in fresh AML blasts and provides a simple means to identify patients for future enrollment in clinical trials with F14512.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963178.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


53. Taksin AL, Legrand O, Raffoux E, de Revel T, Thomas X, Contentin N, Bouabdallah R, Pautas C, Turlure P, Reman O, Gardin C, Varet B, de Botton S, Pousset F, Farhat H, Chevret S, Dombret H, Castaigne S: High efficacy and safety profile of fractionated doses of Mylotarg as induction therapy in patients with relapsed acute myeloblastic leukemia: a prospective study of the alfa group. Leukemia; 2007 Jan;21(1):66-71
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High efficacy and safety profile of fractionated doses of Mylotarg as induction therapy in patients with relapsed acute myeloblastic leukemia: a prospective study of the alfa group.
  • Pivotal phase II studies in acute myeloblastic leukemia (AML) patients in first relapse have used gemtuzumab ozogamicin (GO) (Mylotarg) at a dose of 9 mg/m(2) on days 1 and 14.
  • These studies showed a 26% response rate (13% complete remission (CR) and 13% CRp (complete remission with incomplete platelet recovery)) but with high degree of hematological and liver toxicities.
  • Based on in vitro studies showing a re-expression of CD33 antigenic sites on the cell surface of blasts cells after exposure to GO, we hypothesized that fractionated doses of GO may be efficient and better tolerated.
  • Fifty-seven patients with AML in first relapse received GO at a dose of 3 mg/m(2) on days 1, 4 and 7 for one course.
  • No grade 3 or 4 liver toxicity was observed.
  • No veno-occlusive disease occurred after GO or after hematopoietic stem cell transplantation given after GO in seven patients.
  • [MeSH-major] Aminoglycosides / administration & dosage. Antibodies, Monoclonal / administration & dosage. Antineoplastic Agents / administration & dosage. Leukemia, Myeloid, Acute / drug therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antibodies, Monoclonal, Humanized. Antigens, CD / blood. Antigens, Differentiation, Myelomonocytic / blood. Disease-Free Survival. Drug Administration Schedule. Humans. Middle Aged. Multidrug Resistance-Associated Proteins / blood. P-Glycoprotein / blood. Recurrence. Remission Induction. Sialic Acid Binding Ig-like Lectin 3

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17051246.001).
  • [ISSN] 0887-6924
  • [Journal-full-title] Leukemia
  • [ISO-abbreviation] Leukemia
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Aminoglycosides; 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antigens, CD; 0 / Antigens, Differentiation, Myelomonocytic; 0 / Antineoplastic Agents; 0 / CD33 protein, human; 0 / Multidrug Resistance-Associated Proteins; 0 / P-Glycoprotein; 0 / Sialic Acid Binding Ig-like Lectin 3; 0 / gemtuzumab; 0 / multidrug resistance-associated protein 1
  •  go-up   go-down


54. McHayleh WM, Redner R, Sehgal R, Raptis A, Agha M, Natale J, Luong T, Schlesselman JJ, Foon K, Boyiadzis M: Etoposide and mitoxantrone in newly diagnosed acute myeloid leukemia patients with persistent leukemia after a course of induction therapy with cytarabine and idarubicin. J Clin Oncol; 2009 May 20;27(15_suppl):7073

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Etoposide and mitoxantrone in newly diagnosed acute myeloid leukemia patients with persistent leukemia after a course of induction therapy with cytarabine and idarubicin.
  • : 7073 Background: The goal of induction chemotherapy in acute myeloid leukemia (AML) is complete remission with restoration of normal bone marrow.
  • If residual leukemia is present after the first course of induction therapy, patients receive a second course identical to the first or receive a non-cross resistant antileukemic regimen.
  • METHODS: In a retrospective study of adult patients with newly-diagnosed AML treated at the University of Pittsburgh Cancer Institute between December 2002 and May 2008, we evaluated the efficacy and toxicity of mitoxantrone (10 mg/m<sup>2</sup>/d) and etoposide (100 mg/m<sup>2</sup>/d), both administered intravenously within 5 days as second course therapy of patients not responding to first-course induction therapy with cytarabine and idarubicin.
  • RESULTS: 74 AML patients (mean age 56 years, range: 18-73 years) completed treatment with etoposide and mitoxantrone; 29 (39%) achieved CR.
  • Lower CR rate was associated with unfavorable cytogenetic risk status at diagnosis and higher percent blasts prior to treatment with mitoxantrone and etoposide.
  • CONCLUSIONS: Our study suggests that the combination of etoposide and mitoxantorne is an active and well-tolerated regimen as second-course therapy in newly diagnosed AML patients who have persistent leukemia after a first course of induction therapy with cytarabine and idarubicin.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961456.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


55. Villano JL, Letarte N, Yu JM, Shakir AR, Bressler L: Hematologic adverse events associated with temozolomide (TMZ). J Clin Oncol; 2009 May 20;27(15_suppl):2053

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • : 2053 Background: Secondary acute myeloid leukemia (AML) is reported to occur in 3%-10% of patients treated with alkylating agents for Hodgkin's lymphoma, non-Hodgkin's lymphoma, ovarian cancer, breast cancer, and multiple myeloma.
  • The incidence of secondary AML is greatest at 5-10 years after treatment, and AML often follows myelodysplastic syndrome (MDS).
  • Among these patients, we identified 140 cases that we labeled as major hematologic adverse events: agranulocytosis (8 cases), aplasia (42), aplastic anemia (52), leukemia (26), MDS (6), and lymphoma (6).
  • Risk of leukemia/MDS from our review may also be significant, but length of follow-up is insufficient and the real risk is likely still unknown.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964671.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


56. Batty G, Kantarjian H, Issa JJ, Garcia-Manero G, Pierce S, O'Brien S, Jabbour E, Cortes J, Ravandi F: Feasibility of hypomethylating therapy in patients with renal insufficiency. J Clin Oncol; 2009 May 20;27(15_suppl):7089

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: We investigated the outcomes of pts with RI and MDS, chronic myelomonocytic leukemia (CMML), or acute myeloid leukemia (AML) receiving therapy with HA.
  • We used the International Working Group criteria to evaluate the response rates.
  • RESULTS: Forty-two pts with sCr ≥ 1.5 mg/dL (including 17 with MDS, 16 with AML, and 9 with CMML) were treated with DAC or 5AZA alone or in combination with other agents (primarily histone deacetylase inhibitors).
  • The incidence of complications, DA, and the response rate were not significantly different for pts with sCr > 2.0 mg/dL.
  • CONCLUSIONS: The use of HA is well tolerated in pts with MDS and AML and RI who achieved comparable OR rates to those without RI.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961273.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


57. Yamamoto K, Yakushijin K, Kawamori Y, Minagawa K, Katayama Y, Matsui T: Translocation (7;9)(q22;q34) in therapy-related myelodysplastic syndrome after allogeneic bone marrow transplantation for acute myeloblastic leukemia. Cancer Genet Cytogenet; 2007 Jul 1;176(1):61-6
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Translocation (7;9)(q22;q34) in therapy-related myelodysplastic syndrome after allogeneic bone marrow transplantation for acute myeloblastic leukemia.
  • Reciprocal translocations involving the long arm of chromosome 7 are relatively rare cytogenetic aberrations in myelodysplastic syndrome (MDS) and acute myeloblastic leukemia (AML).
  • A 44-year-old woman was initially given a diagnosis of de novo AML M6A with a normal karyotype.
  • Because the same translocation reappeared and sustained for more than 8 months after second stem cell transplantation, we revised the diagnosis as therapy-related MDS after allogeneic transplantation.
  • Considering two other such reported cases of AML, the t(7;9)(q22;q34) may be a novel recurrent translocation in myeloid malignancies.
  • [MeSH-major] Bone Marrow Transplantation / adverse effects. Chromosomes, Human, Pair 7. Chromosomes, Human, Pair 9. Leukemia, Myeloid, Acute / therapy. Myelodysplastic Syndromes / genetics. Translocation, Genetic


58. Gupta N, Diderichsen PM, Steinberg J, Ricker JL, Humerickhouse R, Awni W, Pradhan R: Population pharmacokinetic (PK) analysis of ABT-869 in solid tumors and acute myelogenous leukemia (AML) patients. J Clin Oncol; 2009 May 20;27(15_suppl):3567

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Population pharmacokinetic (PK) analysis of ABT-869 in solid tumors and acute myelogenous leukemia (AML) patients.
  • The objectives of this analysis were to understand the population pharmacokinetics of ABT-869 and explore the effect of several demographic/disease state covariates influencing ABT-869 disposition.
  • METHODS: A population PK analysis of 181 patients (pts) enrolled in two phase 1 (multiple types of solid tumors and AML) and three phase 2 monotherapy studies (non-small cell lung cancer, hepatocellular carcinoma [HCC] and renal cell carcinoma) was conducted.
  • Available plasma concentrations obtained after intensive and sparse pre-dose PK sampling were analyzed by population PK using the non linear mixed effects modeling (NONMEM) approach.
  • Potential covariates including body weight, body surface area (BSA), age, sex, creatinine clearance (CrCL) and disease state (HCC vs. non-HCC pts) were tested.
  • Oral clearance (CL/F) was not affected by body weight (range 35-177 kg); however, apparent volume of distribution (V/F) increased by 6L per 0.1 mg/m<sup>2</sup> increase in BSA.
  • CrCL (39.9-290.3 ml/min) was not a significant covariate on V/F and CL/F suggesting renally impaired pts do not require a different dose/dosing regimen.
  • Race and impaired renal function does not appear to alter PK.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961681.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


59. Kunivayalil S, Jain A, Satheesh C, Tejinder S, Lakshmaiah K, Suresh TM, Lokanatha D, Babu G: A comparative study of single-dose pegfilgrastim versus daily filgrastim in patients with acute myeloid leukemia. J Clin Oncol; 2009 May 20;27(15_suppl):e18005

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A comparative study of single-dose pegfilgrastim versus daily filgrastim in patients with acute myeloid leukemia.
  • It can be used during induction and consolidation chemotherapy in acute myeloid leukemia (AML).
  • Few studies addressed the use of pegylated filgrasim in AML.
  • Safety profile and complete remission status did not differ between the two groups.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964003.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


60. Fernandez HF, Sun Z, Litzow MR, Luger SM, Paietta EM, Dewald G, Ketterling RP, Rowe JM, Lazarus HM, Tallman MS: A randomized trial of anthracycline dose intensification during induction of younger patients with acute myeloid leukemia: Results of Eastern Cooperative Oncology Group study E1900. J Clin Oncol; 2009 May 20;27(15_suppl):7003

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A randomized trial of anthracycline dose intensification during induction of younger patients with acute myeloid leukemia: Results of Eastern Cooperative Oncology Group study E1900.
  • : 7003 Background: In younger adults with newly diagnosed acute myeloid leukemia (AML), anthracycline dose intensification during induction may improve complete remission (CR) rates; however, an improvement in overall survival (OS) in a randomized trial has not been demonstrated.
  • METHODS: Adult patients with previously untreated AML were randomized to receive either SDD (45 mg/m<sup>2</sup>/d) or HDD (90 mg/m<sup>2</sup>/d) each for 3days combined with standard-dose cytarabine (100 mg/m<sup>2</sup>/d) for 7 days by continuous intravenous infusion.
  • Those achieving a CR were allocated to allogeneic hematopoietic stem cell transplantation (HSCT) or high-dose cytarabine (with or without a single dose of gemtuzumab ozogamicin) prior to autologous HSCT.
  • There were no differences in patient demographics or disease characteristics between the two groups at presentation.
  • In younger AML patients a higher dose of anthracycline in induction should be considered the new standard of care.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961375.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


61. Popat UR, Saliba R, Hosing C, Khouri I, Alousi AM, Giralt SA, de Lima MJ, Qazilbash MH, Champlin R, Anderlini P: Age at diagnosis does not adversely affect outcome in patients with Hodgkin's Disease (HD) after autologous transplantation. J Clin Oncol; 2009 May 20;27(15_suppl):e19507

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Age at diagnosis does not adversely affect outcome in patients with Hodgkin's Disease (HD) after autologous transplantation.
  • : e19507 Background: Age at diagnosis is a poor prognostic factor for overall survival after standard therapy for HD.
  • Whether older age is a prognostic factor for outcome after autologous transplantation is not known.
  • We sought to evaluate the effect of older age at diagnosis on transplant outcome.
  • Seventy two patients (29%) were older than 40 years of age at the time of initial diagnosis.
  • At transplantation, 63 (25%) were in complete remission (CR); 148 (60%) were in partial remission (PR); and 37 (15%) had stable (SD) or progressive disease (PD).
  • Peripheral blood stem cells were used as stem cell source in 241 (97%) patients.
  • The cumulative incidence of non-relapse mortality at 1 year was 1.6%.
  • The cumulative incidence of secondary MDS or AML was 8%.
  • In univariate analysis, disease status (p<0.001) and number of prior chemotherapy regimens (p=0.007) were the only factors significantly predicting OS.
  • Disease status was the only factor significant (p<0.01) in a multivariate analysis with a hazard ratio of 2.7 (1.1-6.9) and 9.2 (3.4-25) for patients in PR, and SD/PD respectively (CR reference group).
  • Age at diagnosis was not a significant factor (see table ).
  • CONCLUSIONS: High-dose chemotherapy and autologous transplantation abrogate the adverse impact of age at diagnosis in patients with HD.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27960864.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


62. Ding W, Knox TR, Smoley SA, Van Dyke DL, Kay NE: Cytogenetic abnormalities in mesenchymal stem cells in chronic lymphocytic leukemia (CLL) patients and normal subjects. J Clin Oncol; 2009 May 20;27(15_suppl):e22002

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cytogenetic abnormalities in mesenchymal stem cells in chronic lymphocytic leukemia (CLL) patients and normal subjects.
  • : e22002 Background: Mesenchymal stem cells (MSC) residing in the marrow support hematopoiesis and protect cancer cells from undergoing cell death induced by chemotherapy.
  • Recent reports have described clonal cytogenetic abnormalities in the MSC of acute myeloid leukemia and myelodysplastic syndrome patients.
  • After 3-4 non-stimulated cell culture passages, the karyotype was analyzed in 5-40 metaphase cells from each subject Abnormalities were considered clonal using the accepted convention of the same chromosomal gain or rearrangement in 2 or more cells or loss in at least 3 cells.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963169.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


63. Iliopoulou EG, Kountourakis P, Karamouzis MV, Doufexis D, Ardavanis A, Baxevanis CN, Rigatos G, Papamichail M, Perez SA: A phase I trial of adoptive transfer of allogeneic natural killer (NK) cells in patients (pts) with advanced non-small cell lung cancer (NSCLC). J Clin Oncol; 2009 May 20;27(15_suppl):3001

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase I trial of adoptive transfer of allogeneic natural killer (NK) cells in patients (pts) with advanced non-small cell lung cancer (NSCLC).
  • : 3001 Background: HLA-mismatched NK cells have been found effective in acute myeloid leukemia pts.
  • RESULTS: Between 11/2007 and 11/2008 16 pts (performance status 0-1) were enrolled; 1 pt had rapid disease progression before treatment.
  • Pts characteristics: M/F 12/4; histology: adenocarcinoma/squamous cell carcinoma 13/3; stage IIIb/IV 2/14; 1<sup>st</sup>/2<sup>nd</sup> line treatment 13/3; median age 64 years (range, 50-71).
  • With a median follow-up of 6 months (range, 1-14) 3 pts with partial response and 7 pts with disease stabilization were recorded.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962051.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


64. Hirte HW, McGuire W, Edwards R, Husain A, Hoskins P, Michels J, Matulonis U, Sexton C, Michelson G: A phase II trial of voreloxin in women with platinum-resistant ovarian cancer. J Clin Oncol; 2009 May 20;27(15_suppl):5559

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Clinical activity has been observed in ovarian cancer and AML.
  • METHODS: Pts may have received ≤ 3 prior platinum regimens plus one additional non-platinum regimen.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962535.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


65. Ayan I, Kebudi R, Ozger H, Yaman Agaoglu F, Gorgun O, Bilgic B, Eralp L, Dizdar Y, Darendeliler E: Childhood osteosarcoma: Evaluation of 94 cases. A single institution study. J Clin Oncol; 2009 May 20;27(15_suppl):10040

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Between January 1990 and December 2006, 94 children (53 male, 41 female) with a median age of 13 (5-16) years and a histopathologic diagnosis of osteosarcoma were treated with an institutional chemotherapy regimen comprising of 6 courses (3 pre-, 3 postoperatively) of epirubicin (90 mg/m2), cisplatin(100 mg/m2), and ifosfamide(2 g/m2 × 3 days) every 3 weeks.
  • 26 patients died; 20 of disease, 5 of toxicity, and 1 of second malignancy (acute myeloid leukemia).
  • 5 and 10 year EFS for nonmetastatic patients was superior to those with metastatic disease [62.4 % (95% CI 49.9-79.9 %) vs. 6.9 % (95% CI 0-19.9 %)) (p<0.001).
  • 10 year OS for 18 patients (11 metastatic at diagnosis) who progressed during preoperative chemotherapy was 13 % vs. 75 % for those who didnot have progressive disease (p< 0.001).
  • Histologic response (<90 percent necrosis vs ≥90 percent) significantly correlated with 5 year EFS (31 % vs 67.6 %, p=0.023) but not with OS (57.7 % vs 76.5 %, p=0.13).
  • CONCLUSIONS: The presence of metastases at diagnosis was the most significant characteristic influencing outcome.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962466.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


66. Plunkett W, Thomas DA, O'Brien SM, Federl S, Giles FJ, Nicol SJ, Gill J, Zhao L, Ravandi F, Kantarjian H: Phase I study of pemetrexed in patients with relapsed or refractory acute leukemia or lymphoid blast phase chronic myelogenous leukemia. J Clin Oncol; 2009 May 20;27(15_suppl):7068

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase I study of pemetrexed in patients with relapsed or refractory acute leukemia or lymphoid blast phase chronic myelogenous leukemia.
  • The purpose of this phase I trial was to define the dose-limiting toxicity (DLT), maximum tolerated dose (MTD), and recommended phase II dose (RP2D) of pemetrexed given with vitamin supplementation to patients with relapsed or refractory leukemia.
  • METHODS: Patients ≥15 years of age were enrolled with relapsed or refractory leukemia, Eastern Cooperative Oncology Group performance status ≤2, adequate renal and hepatic function, and life expectancy of ≥6 weeks.
  • RESULTS: Twenty-two patients entered the trial; median age was 50 years (range: 18-75); 15 patients had acute myeloid leukemia and 7 patients had acute lymphocytic leukemia (ALL).
  • Two patients were ineligible and did not receive study drug.
  • At the 1,200 and 1,500 mg/m<sup>2</sup> dose levels, 1 patient per level developed grade (G) 3-4 liver enzyme and bilirubin elevations attributed to sepsis.
  • At the 3,600 mg/m<sup>2</sup> dose level, 1 patient had a G3 liver enzyme elevation and 2 added patients also had G3 liver toxicity.
  • In addition, 2 patients in the 3,600 mg/m<sup>2</sup> cohort developed G2 liver abnormalities.
  • Based on liver toxicities, the DLT dose level was established at 3,600 mg/m<sup>2</sup>.
  • Two patients died during the study due to disease progression and 1 patient discontinued due to a subdural hematoma of unknown cause.
  • PK and PD data were not available for this report.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961463.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


67. Jabbour E, Faderl S, Ravandi F, Konopleva M, Verstovsek S, Cortes J, Wierda W, Newsome WM, Yang H, Kantarjian H, Garcia-Manero G: Phase II study of vorinostat (V) in combination with idarubicin and high-dose cytarabine (IA) as front-line therapy in patients (pts) with high-risk myelodyplsatic syndrome (MDS) or acute myeloid leukemia (AML). J Clin Oncol; 2009 May 20;27(15_suppl):7004

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II study of vorinostat (V) in combination with idarubicin and high-dose cytarabine (IA) as front-line therapy in patients (pts) with high-risk myelodyplsatic syndrome (MDS) or acute myeloid leukemia (AML).
  • : 7004 Background: Standard induction therapy for pts with AML has not changed over the last 2 decades nor has the outcome of these pts.
  • We designed a phase II study of V with IA as front-line therapy for MDS/AML.
  • METHODS: Pts with untreated int-2/high-risk MDS or AML ages 15-65 with adequate liver and renal functions and PS, and EF ≥ 50% were eligible.
  • 3 pts with relapsed/refractory AML were treated in the run-in phase.
  • 8 (47%) had secondary disease.
  • The median PFS has not been reached.
  • CONCLUSIONS: The combination of IA and V is safe and active in AML/MDS.
  • Results will be compared with those of a parallel IA study at MDACC.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961376.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


68. Cárdenas-Blanco A, Olariou E, Cameron I: Poster - Thurs Eve-28: New brain diffusion analysis method: White matter grey matter dissasociation. Med Phys; 2008 Jul;35(7Part2):3406

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The significance of the present diffusion decay study lies in the combination of three novel procedures to provide a better characterization of the diffusion decay: i) the acquisition of a large number of b-values (96 b-values up to 10,000 s/mm<sup>2</sup> ), ii) the application of a noise correction technique (3) to the acquired data, and iii) the use of a Non Negative Least Squares (NNLS) fitting algorithm to evaluate the diffusion coefficients.
  • The NNLS algorithm is used to fit the corrected data instead of the more commonly used Levenberg-Marquardt algorithm since the NNLS algorithm does not require the number of components to be specified, nor does it need initial estimates of the fitting parameters as input; thus giving it more versatility as a fitting tool for the diffusion decay.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2008 American Association of Physicists in Medicine.
  • (PMID = 28512828.001).
  • [ISSN] 2473-4209
  • [Journal-full-title] Medical physics
  • [ISO-abbreviation] Med Phys
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Keywords] NOTNLM ; Brain / Diffusion / Medical imaging / Medical magnetic resonance imaging / Neural information
  •  go-up   go-down


69. Takahara M, Tsuji G, Ishii N, Dainichi T, Hashimoto T, Kohno K, Kamezaki K, Nagafuji K, Takeuchi S, Moroi Y, Furue M: Mucous membrane pemphigoid with antibodies to the beta(3) subunit of Laminin 332 in a patient with acute myeloblastic leukemia and graft-versus-host disease. Dermatology; 2009;219(4):361-4
Hazardous Substances Data Bank. MINOCYCLINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mucous membrane pemphigoid with antibodies to the beta(3) subunit of Laminin 332 in a patient with acute myeloblastic leukemia and graft-versus-host disease.
  • [MeSH-major] Antibodies / immunology. Cell Adhesion Molecules / immunology. Graft vs Host Disease / immunology. Immunocompromised Host. Leukemia, Myeloid, Acute / immunology. Pemphigoid, Benign Mucous Membrane / immunology

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • MedlinePlus Health Information. consumer health - Pemphigus.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19797892.001).
  • [ISSN] 1421-9832
  • [Journal-full-title] Dermatology (Basel, Switzerland)
  • [ISO-abbreviation] Dermatology (Basel)
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Anti-Bacterial Agents; 0 / Antibodies; 0 / Biomarkers; 0 / Cell Adhesion Molecules; 0 / Glucocorticoids; 0 / kalinin; FYY3R43WGO / Minocycline
  •  go-up   go-down


70. Rubnitz J, Inaba H, Ribeiro R, Pounds S, Pui C, Leung W: Pilot study of haploidentical natural killer cell transplantation in childhood acute myeloid leukemia. J Clin Oncol; 2009 May 20;27(15_suppl):10034

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pilot study of haploidentical natural killer cell transplantation in childhood acute myeloid leukemia.
  • : 10034 Background: In the setting of hematopoietic stem cell transplantation (HSCT), donor natural killer (NK) cells exhibit potent anti-leukemic effects without causing graft-versus-host disease.
  • We hypothesized that the transplantation of purified haploidentical NK cells may be a safe and effective form of consolidation therapy that will reduce the risk of relapse among children with acute myeloid leukemia (AML) who are not treated with HSCT.
  • In this pilot study, we assessed the safety, feasibility, and engraftment of NK cell infusions in 10 patients with AML in first remission.
  • RESULTS: The 10 patients had a median age of 2.5 years (range, 8 months to 21 years) and a median leukocyte count of 62 x 10<sup>9</sup>/L (range, 4 to 487) at diagnosis.
  • Leukemic cell genetic abnormalities included CBFβ-MYH11in 4 cases, RBM15-MKL1in 2 cases, MLL-ENL and MLL-AF9 in 1 case each; 2 cases had no detectable abnormalities.
  • All patients had detectable donor NK cells at one or more time points: donor NK cell chimerism ranged from 0% to 30% during the first 4 weeks after the infusions and was greater than 1% in 9 cases at week 1, 4 cases at week 2, 5 cases at week 3, and 3 cases at week 4.
  • One patient had prolonged NK engraftment (189 days), but no non-hematological toxicity.
  • Grade 3-4 non-hematological toxicity was limited to one respiratory viral infection and one episode of febrile neutropenia.
  • CONCLUSIONS: Haploidentical NK cells can be safely administered to AML patients who are in remission.
  • We have recently opened a new trial to evaluate the efficacy of NK cell therapy in children in first remission of AML.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962581.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


71. Pratz KW, Cho E, Karp J, Levis M, Zhao M, Rudek M, Wright J, Smith BD: Phase I dose escalation trial of sorafenib as a single agent for adults with relapsed and refractory acute leukemias. J Clin Oncol; 2009 May 20;27(15_suppl):7065

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase I dose escalation trial of sorafenib as a single agent for adults with relapsed and refractory acute leukemias.
  • Based on preclinical activity in FLT3 mutant AML, sorafenib was studied in refractory acute leukemia.
  • METHODS: The primary objective was to determine the safety and tolerability of sorafenib in refractory acute leukemias.
  • RESULTS: Fifteen patients (13 = AML, 2 = ALL) were enrolled (ages 37-85) and treated on three dosing schedules (400 mg BID x 14 d, 400 mg BID x 21 days, 600 mg BID x 21days) of single agent sorafenib.
  • No patients met criteria for complete or partial response, but 11 of 15 (73%) patients experienced stable disease as best response, with 6 showing a reduction in bone marrow blasts after only one cycle, half of who experienced a >50% reduction in bone marrow blasts.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961441.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


72. Kadia TM, Faderl S, Estrov Z, Konopleva M, George S, Lee W, Puzanov I, Chen A, Kantarjian H, Ravandi F: Final results of phase I and pharmacokinetic study of SJG-136 administered on a daily x 5 schedule. J Clin Oncol; 2009 May 20;27(15_suppl):e13506

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Here we report the results of a CTEP-sponsored phase I trial of SJG-136 administered on a daily x 5 schedule in pts with relapsed or refractory (R/R) leukemias.
  • METHODS: Previously treated pts with R/R acute leukemias (AML, ALL, high risk MDS, CML blast phase) or R/R CLL with adequate organ function and ECOG performance status of ≤ 2 were eligible for the study.
  • Thirteen (81%) pts had R/R AML, and 3 (19%) had R/R ALL of which 5 (31%) had diploid and 6 (38%) had adverse cytogenetics.
  • Other non-dose limiting toxicities included nausea, dyspnea, fatigue, bloating, and insomnia.
  • One pt had a PR, 8 pts had stable disease, and 6 had progression.
  • CONCLUSIONS: SJG-136 is safe and active in patients with advanced leukemias.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961262.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


73. Fauzdar A, Mahajan A, Jain D, Mishra M, Raina V: Amplification of RUNX1 gene in two new cases of childhood B-cell precursor acute lymphoblastic leukemia: A case report. J Clin Oncol; 2009 May 20;27(15_suppl):e21000

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Amplification of RUNX1 gene in two new cases of childhood B-cell precursor acute lymphoblastic leukemia: A case report.
  • : e21000 Background: Chromosome abnormalities of leukemia cells have important prognostic significance in childhood acute lymphoblastic leukemia (ALL).
  • B-cell precursor acute lymphoblastic leukemia (BCP-ALL) ETV6/RUNX1 (alias TEL/AML1) is most frequent i.e.
  • We report two new cases with Pre B- cell ALL without ETV6/RUNX1 rearrangement, showing amplification of AML1 gene detected by FISH analysis.
  • RESULTS: In first case a 3-year girl with four copies of AML (RUNX1) gene were observed in 95% of the cell with normal two copies of TEL (ETV6) gene in both interphase and metaphase FISH.
  • In second case, a 4-year male we observed four copies of AML and two copies of TEL gene in more than 80% of cells.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27960689.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


74. Spadaro P, Ingemi M, Pitini V, Arrigo C, Soto Parra H: Myelodysplastic syndromes developing after imatinib therapy for GIST. J Clin Oncol; 2009 May 20;27(15_suppl):10532

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Between January 2007 and December 2008, bone marrow samples for morphologic analysis, FISH and classical cytogenetics were obtained from 49 pts. (30 male; 19 female, mean age 62) with unresectable or metastatic GIST before and during treatment with 400 mg/d of imatinib.
  • For pts. with progressive disease (15 pts.) or exon 9 mutant disease (5 pts.
  • All pathologic material was reviewed to identify pts. with MDS or AML according to the WHO classification.
  • One patient developed a RAEB-1 with monosomy 7 which rapidly transformed into AML.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963910.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


75. Ghavamzadeh A, Hashemi S, Alimoghaddam K, Nasri Moghaddam Z, Shadpour M, Jalili M: Phase II trial of old age acute myeloid leukemia treatment by arsenic trioxide and low-dose subcutaneous cytosin arabinoside. J Clin Oncol; 2009 May 20;27(15_suppl):7075

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II trial of old age acute myeloid leukemia treatment by arsenic trioxide and low-dose subcutaneous cytosin arabinoside.
  • : 7075 Background: AML is a disease of old age, but unfortunately due to several factors standard treatment can not be delivered to these patients.
  • Patients couldn't tolerate standard treatment of AML due to old age or comorbid disorders.
  • CONCLUSIONS: Although prognosis of old age AML remain poor, but with this type of treatment RR is acceptable.
  • In this very high-risk group of very old AML, combination of ATO and ARA-C possibly could improve survival.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961458.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


76. Cheng PC, Crane J, Hunter T: Combination of bortezomib with a FLT3 inhibitor potentiates inhibition of proliferation and apoptosis of AML in vitro. J Clin Oncol; 2009 May 20;27(15_suppl):e14551

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Combination of bortezomib with a FLT3 inhibitor potentiates inhibition of proliferation and apoptosis of AML in vitro.
  • : e14551 Background: FLT3 receptor tyrosine kinase activating mutations contribute to leukemogenesis and poor prognosis in approximately 30% of acute myeloid leukemia (AML).
  • METHODS: In the course of conducting a synthetic lethality screen with a FLT3 inhibitor on the Ba/F3 murine cell line stably expressing human FLT3 or FLT3-ITD, we identified bortezomib, a proteasome inhibitor, as having potent activity against FLT3-ITD cells.
  • The effects of drugs on proliferation, apoptosis, and phosphosignaling were quantified in Ba/F3 cells and in the HL60 (WT FLT3) and MV4-11 (FLT3-ITD) human cell lines, using an MTS- based colorimetric assay, caspase 3 and 7 activity assays, and immunoblotting, respectively.
  • When the FLT3 inhibitor and bortezomib were used at IC25 concentrations, a more pronounced inhibition of cell proliferation was observed when they were used in combination than with either alone.
  • CONCLUSIONS: Bortezomib preferentially kills FLT3- ITD cells, showing a four-fold more potent inhibition of cell proliferation, induces apoptosis, and abrogates activation of FLT3 and its downstream effector pathways.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963616.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


77. Ogawa M, Sakashita K, Zhao XY, Hayakawa A, Kubota T, Koike K: Analysis of histone modification around the CpG island region of the p15 gene in acute myeloblastic leukemia. Leuk Res; 2007 May;31(5):611-21
MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Analysis of histone modification around the CpG island region of the p15 gene in acute myeloblastic leukemia.
  • Seven of 11 patients with acute myeloblastic leukemia (AML) had allele(s) in which more than half of 27 CpG sites in the p15 gene were methylated.
  • The p15 CpG island region was surrounded with both the acetylated histone H3 (AcH3) and dimethylated histone H3-lysine 9 (MeH3K9) in bone marrow cells of AML patients, whereas with AcH3 alone in normal marrow cells.
  • The p15 CpG islands of DNA immunoprecipitated with anti-AcH3 antibody and anti-MeH3K9 antibody were not always unmethylated and methylated, respectively, in the patients.
  • These results suggest perturbed modifications of histone H3 around the p15 CpG island region in AML.
  • [MeSH-major] CpG Islands. Cyclin-Dependent Kinase Inhibitor p15 / genetics. DNA Methylation. Histones / metabolism. Leukemia, Monocytic, Acute / genetics. Leukemia, Myeloid, Acute / genetics. Leukemia, Myelomonocytic, Acute / genetics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17074388.001).
  • [ISSN] 0145-2126
  • [Journal-full-title] Leukemia research
  • [ISO-abbreviation] Leuk. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Cyclin-Dependent Kinase Inhibitor p15; 0 / Histones
  •  go-up   go-down


78. Ritchie EK, Roboz G, Hinchcliff K, Curcio T, Scandura J, Feldman E: Phase I trial of laromustine in combination with infusional ara-C in elderly patients over age 60 with newly diagnosed AML or high-grade MDS. J Clin Oncol; 2009 May 20;27(15_suppl):7054

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase I trial of laromustine in combination with infusional ara-C in elderly patients over age 60 with newly diagnosed AML or high-grade MDS.
  • : 7054 Background: Laromustine is a novel sulfonylhydrazine-alkylating agent with activity in acute myeloid leukemia (AML).
  • Laromustine in phase I and II trials shows activity in patients with relapsed/refractory leukemia (1) and elderly patients with new AML (2).
  • Based on this data, a phase I study to evaluate the safety and efficacy of combining escalating doses of laromustine with infusional ara-C in AML and MDS patients over 60.
  • METHODS: Laromustine 300 mg/m2 (cohort 1, n = 6), 400 mg/m2 (cohort 2, n = 5) and 500 mg/m2 (cohort 3) was administered by IV infusion over 1 hour on day 1 in combination with ara-C 100 mg/m2/day as a continuous infusion for 7 days.
  • Patients achieving CR after induction therapy were offered up to 2 cycles of consolidation therapy for a maximum cumulative laromustine dose of 1,000 mg/m2.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961420.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


79. Bello CM, Yu D, Zhu W, Wetzstein GA, Lancet JE: Outcomes following induction chemotherapy in patients with AML arising from MDS: Analysis of prognostic factors. J Clin Oncol; 2009 May 20;27(15_suppl):7088

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Outcomes following induction chemotherapy in patients with AML arising from MDS: Analysis of prognostic factors.
  • : 7088 Background: Secondary acute myeloid leukemia (sAML) arising from myelodysplasia (MDS) or a myeloproliferative neoplasm (MPN) has a poor prognosis.
  • METHODS: Retrospective chart review of patients with untreated AML from MDS/MPN treated with standard induction therapy from January 2004 to September 2008.
  • Multivariable analysis indicated that the same three factors were significantly negatively associated with CR/CRp as well as OS: PR cytogenetics, prior treatment with DM/L, and long transformation to AML on log scale.
  • Only 32% of the group that received prior treatment with a DM/L achieved CR/CRp compared to 78% in non DM/L-treated patients (OR = 0.13, 95% CI: 0.04-0.42).
  • The median OS for those treated with a DM/L was 3.7 mo compared to 10.5 mo for non DM/L-treated patients (p < 0.0001).
  • CONCLUSIONS: Prior MDS treatment with a DM/L, PR cytogenetics and long transformation to AML are independent negative prognostic factors for response and OS in patients with sAML following induction therapy, suggesting that such patients may be better served by novel approaches, and that stratification for these risk factors should be considered in future clinical trials.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961482.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


80. Pemmaraju N, Kantarjian H, Ravandi F, O'Brien S, Wierda W, Thomas D, Garcia-Manero G, Borthakur G, Pierce S, Cortes J: Acute myeloid leukemia (AML) in adolescents and young adults (AYA): The M. D. Anderson Cancer Center (MDACC) experience. J Clin Oncol; 2009 May 20;27(15_suppl):7051

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Acute myeloid leukemia (AML) in adolescents and young adults (AYA): The M. D. Anderson Cancer Center (MDACC) experience.
  • : 7051 Background: AML is a heterogeneous group of hematopoietic neoplasms demonstrating clonal proliferation of myeloid precursors and is typically a disease of older adults.
  • Little is known about outcomes of AYA with AML.
  • METHODS: We retrospectively analyzed all patients (pts) with AML treated at MDACC from 1965 to 2008.
  • RESULTS: Among 3,934 adult AML pts treated during this period, 163 pts (4%) were AYA with median age of 19 yrs.
  • This cohort included 27 (17%) pts with Core Binding Factor (CBF)-AML [inv(16), t(8:21)] and 19 pts (12%) with acute promyelocytic leukemia (APL).
  • Complete remission (CR) rates were 89% for CBF AML, 79% for APL, and 75% for all other pts.
  • Outcome is better for pts with CBF leukemia (3 yr survival 56%, sustained CR 49%) and APL (3 yr survival 51%, sustained CR 36%) compared to other AML (3 yr survival 28%, sustained CR 24%).
  • CONCLUSIONS: The outcome of AYA pts with AML is significantly better than for older adults with AML.
  • Despite the advances in treatments over time, there is still significant room for improvement, particularly among those AYA with AML other than CBF and APL.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961415.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


81. B'Chir Hamzaoui S, Abdallah M, Baili L, Bouslama K, Harmel A, Ennafa M, M'Rad S, Ben Dridi M: [Takayasu's arteritis associated with acute myeloblastic leukemia]. J Mal Vasc; 2006 Dec;31(5):280-3
MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Takayasu's arteritis associated with acute myeloblastic leukemia].
  • [Transliterated title] Association artérite de Takayasu et leucémie aiguë myéloblastique.
  • INTRODUCTION: We present one patient with acute myeloblastic leukemia diagnosed two months after the onset of Takayasu's arteritis.
  • EXEGESIS: A 21-year old woman with a previous history of erythema nodosum and episcleritis was admitted for a left cervical mass.
  • Histological findings of the carotid aneurism revealed a granulomatous giant cell arteritis consistent with Takayasu's arteritis.
  • Two weeks after, she was discharged, elevated white cell count (440.000/mm3 ) was disclosed.
  • A bone marrow aspirate documented an acute myeloid leukemia.
  • CONCLUSION: Leucocytoclastic vasculitis and polyarteritis nodosa occur in acute myeloid leukemia, but the association with Takayasu's arteritis is new.
  • In our knowledge, only two documented cases of Takayasu's arteritis in association with acute myeloblastic leukemia have been published.
  • [MeSH-major] Aortic Valve Stenosis / etiology. Aortic Valve Stenosis / radiography. Erythema Nodosum / complications. Leukemia, Myeloid, Acute / complications. Takayasu Arteritis / etiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17202981.001).
  • [ISSN] 0398-0499
  • [Journal-full-title] Journal des maladies vasculaires
  • [ISO-abbreviation] J Mal Vasc
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


82. Goldman S, Coiffier B, Reiter A, Younes A, Cairo MS, International TLS Expert Panel: A medical decision tree for the prophylaxis (P) and treatment (T) of tumor lysis syndrome (TLS): An international TLS consensus panel. J Clin Oncol; 2009 May 20;27(15_suppl):e17575

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A medical decision tree for the prophylaxis (P) and treatment (T) of tumor lysis syndrome (TLS): An international TLS consensus panel.
  • METHODS: We convened an international panel (N = 17) of experts in pediatric and adult hematological malignancies and solid tumors (ST) to develop a medical decision tree for the P and T of TLS based on the risk classification (low, medium, high) and management recommendations of Coiffier et al (J Clin Oncol.
  • 2008) Results: Patients without evidence of LTLS were assigned to either low-risk disease (LRD), medium-risk (MRD), or high-risk (HRD).
  • Risk factors included pathological classification stage, bulk, disease burden (WBC/LDH) and renal impairment/involvement.
  • HRD was assigned to patients with either B-ALL, ALL/AML ≥100K/mm<sup>3</sup>, BL/LL stage III/IV, and/or high LDH, DLBCL/PTCL/MCL/ATL with bulky and elevated LDH and patients with MRD with renal impairment/involvement.
  • MRD consisted of ALL ≤100K/mm<sup>3</sup>, AML 25-100K/mm<sup>3</sup>, BL/LL stage I/II and low LDH, childhood ALCL, DLBCL/PTCL/MCL/ATL non-bulky but elevated LDH, CLL treated with targeted therapy, and LRD with renal impairment/involvement.
  • LRD consisted of ST (except bulky sensitive to cytotoxic therapy [MRD]), CML, MM, HL, other NHL and AML <25K/mm<sup>3</sup>.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963935.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


83. Dutreix C, Huntsman Labed A, Roesel J, Lanza C, Wang Y: Midostaurin: Review of pharmacokinetics (PK) and PK/pharmacodynamic (PD) relationship in AML/MDS patients. J Clin Oncol; 2009 May 20;27(15_suppl):e14540

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Midostaurin: Review of pharmacokinetics (PK) and PK/pharmacodynamic (PD) relationship in AML/MDS patients.
  • : e14540 Background: Midostaurin is a multi-tyrosine-kinases inhibitor targeting class III tyrosine-protein-kinases, including Fms-like tyrosine kinase-3 (FLT3), involved in hematopoiesis and leukemia.
  • METHODS: The two studies presented here involved patients with wild-type or FLT3-mutated de novo (phase Ib) or relapsed (phase II) AML or MDS.
  • However, evaluation of available bone marrow blast (BM) response data revealed that a much higher midostaurin plasma would be needed for a satisfactory BM response.
  • These results support the ongoing phase III AML study in AML FLT3-mutated patients with midostaurin given in combination with chemotherapy.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963644.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


84. Singh T, Satheesh C, Ankit J, Sajeevan KV, Appaji L, Arunakumari B, Padma M, Mamatha HS: Use of Port-A-Cath in pediatric cancer patients: Experience from a tertiary cancer center in south India. J Clin Oncol; 2009 May 20;27(15_suppl):e20747

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Disease distribution included ALL(80%), AML(5%), NHL(5%), neuroblastoma (5%) and RMS (5%).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962033.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


85. Garcia-Manero G, Luger S, Venugopal P, Maness L, Wetzler M, Coutre S, Stock W, Borthakur G, Chiao J, Kantarjian H: A randomized phase II study of sapacitabine, an oral nucleoside analogue, in elderly patients with AML previously untreated or in first relapse or previously treated MDS. J Clin Oncol; 2009 May 20;27(15_suppl):7021

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A randomized phase II study of sapacitabine, an oral nucleoside analogue, in elderly patients with AML previously untreated or in first relapse or previously treated MDS.
  • : 7021 Background: Sapacitabine is a novel nucleoside analogue with a unique ability to cause irreparable single-strand DNA breaks and induce G2 cell cycle arrest.
  • It is orally administered and has demonstrated promising anti-leukemic activity against relapsed or refractory AML and MDS in a phase 1 trial.
  • METHODS: Eligible patients must be ≥70 years with AML previously untreated or in first relapse or ≥60 years with MDS previously treated with hypomethylating agents.
  • The planned sample size is 60 AML patients and 60 MDS patients.
  • RESULTS: As of December 2008, 60 AML and 13 MDS patients were enrolled and had ≥ 30 days of follow-up.
  • Preliminary efficacy data were available for the AML stratum.
  • Eight deaths of all causes occurred within 30 days of randomization and all were in the AML stratum (13%).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961383.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


86. Ghavamzadeh A, Allahyari A, Alimoghaddam K, Karimi A, Shamshiri A, Abolhasani R, Manookian A, Asadi M, Khatami F: Outpatient versus inpatient autologous stem cell transplantation for malignant hematologic disorders. J Clin Oncol; 2009 May 20;27(15_suppl):7042

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Outpatient versus inpatient autologous stem cell transplantation for malignant hematologic disorders.
  • : 7042 Background: High-dose chemotherapy with autologous stem cell support is utilized for the treatment of a variety of malignancies including Hodgkin/non-Hodgkins lymphoma and acute leukemias.
  • The aim of this study was to compare the time of engraftment and mortality rate and cost of neutropenic treatment in outpatient versus inpatient autologous stem cell transplantation (SCT).
  • METHODS: 9 outpatients (5 HL, 2 NHL, and 2 AML) were compared with 32 inpatients (15 HL, 8 NHL, and 9 AML; for whom the outpatient facilities were not ready) from May 2008 to December 2008.
  • They received conditioning regimen (CEAM for NHL and HL, busulfan and etoposide for AML) and stem cell infusion in hospital.
  • The day after SCT, outpatient group were discharged and followed by outpatient SCT team, and to be re-hospitalized in case of febrile neutropenia, after sepsis workup and performing chest x-ray, they were received the first dose of antibiotic in hospital and treatment continued in home.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961405.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


87. Rangarajan B, Prabhash K, Nair R, Menon H, Jain P, Kannan S, Jeevangi NK, Bagal B, Parikh PM, Kurkure PA: Rater. J Clin Oncol; 2009 May 20;27(15_suppl):e20678

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Inclusion criteria were diagnosis of hematolymphoid malignancy, neutropenic febrile episode secondary to chemotherapy or during induction therapy of acute leukemia and more than 18 years of age All patients were risk stratified, hospitalized and treated with broad-spectrum, empiric, intravenous antibiotic therapy until recovery or outcome of the event.
  • We subsequently analyzed the subset of Acute Myeloid Leukemia (AML) patients as they were the majority comprising of 62/81 episodes.
  • The subset of AML patients risk stratified according to MASCC risk index showed sensitivity, specificity, PPV, NPV and accuracy of 71%, 25.5%, 11%, 87.5%, 31% respectively.
  • This trend is also seen in the subset analysis of AML patients.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961676.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


88. Tsai DE, Wang W, Reshef R, Vogl D, Stadtmauer E, Andreadis C, Carlson A, Luger S: Effect of bexarotene on platelet counts in patients undergoing cancer treatment: An analysis of clinical trials in lung cancer and leukemia. J Clin Oncol; 2009 May 20;27(15_suppl):e20533

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effect of bexarotene on platelet counts in patients undergoing cancer treatment: An analysis of clinical trials in lung cancer and leukemia.
  • : e20533 Background: Bexarotene (Bex) is an oral retinoid X receptor agonist with activity against cutaneous T cell lymphoma and currently under investigation for other malignancies.
  • In patients receiving this agent for acute myeloid leukemia (AML), we noted increases in platelet counts.
  • METHODS: We analyzed platelet count data from 3 Bex clinical trials encompassing non-small cell lung cancer (NSCLC) and AML.
  • Similar findings were seen in a phase I monotherapy trial in AML where 5/18 (28%) patients achieved platelet transfusion independence with peak platelet counts of 40-91 K/uL.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27960979.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


89. Lannert H, Lenze M, Able T, Park BJ, Lenze A, Meissner S, Eckstein V, Ho AD, Leicht S, Franz T: Changes in phosphorylation and dephosphorylation status of cytoskeleton and their regulator proteins in CD34+ stem cells after G-CSF stimulation and in AML. J Clin Oncol; 2009 May 20;27(15_suppl):e22067

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Changes in phosphorylation and dephosphorylation status of cytoskeleton and their regulator proteins in CD34+ stem cells after G-CSF stimulation and in AML.
  • It is a dynamic structure that maintains cell shape, enables cellular motion.
  • In this study we investigated the expression of cytoskeleton proteins in native hematopoietic CD34+ stem cells from BM in comparison to mobilized peripheral blood stem cells (mPBSCs) from G-CSF stimulated donors as well as CD34+ cells from AML.
  • METHODS: An Auto-MACS (Miltenyi) and FACS Vantage SE cell sorter (Becton Dickinson) was used to process high enriched (>99%) CD34+ cells fractions from MNCs.
  • Stathmin is overexpressed in G-CSF mobilized hematopoietic stem cells and in AML in his active 'dephosphorylated' form.
  • Our results show, that mobilized stem cells "in vivo" and AML cells increase cytoskeleton proteins expression and cause a complex phosphorylation status, which may explain the regulation of migration and metastasis.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963210.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


90. Hollmig K, Waheed S, Nair B, Haessler J, Petty N, Pineda-Roman M, Alsayed Y, van Rhee F, Crowley J, Barlogie B: MDS-associated cytogenetic abnormalities (MDS-CA) after total therapy (TT) regimens for newly diagnosed multiple myeloma (MM): Apparent surge after introduction of post-transplant consolidation chemotherapy (CONS) in TT2 and TT3. J Clin Oncol; 2009 May 20;27(15_suppl):8595

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • CONCLUSIONS: Despite reduced induction chemotherapy prior to and CONS after tandem melphalan (200mg/m2)-based autotransplants from 4 in TT2 to 2 in TT3, overall and persistent MDS-CA increased significantly in TT3.
  • Clinical MDS and AML were rarely observed and a full account of hematopathologic findings will be presented.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962291.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


91. Pardee TS, Zuber J, Lowe SW: Effects of the Flt3 ITD on response to chemotherapy in a murine model of acute myeloid leukemia. J Clin Oncol; 2009 May 20;27(15_suppl):7060

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effects of the Flt3 ITD on response to chemotherapy in a murine model of acute myeloid leukemia.
  • : 7060 Background: Acute myeloid leukemia (AML) is an aggressive, genetically heterogeneous malignancy.
  • The Flt3 receptor tyrosine kinase containing an internal tandem duplication (Flt3 ITD) is a common mutation in AML and associated with a poor prognosis; however, its effect on chemotherapy response is currently unknown.
  • METHODS: Murine AML was generated by retroviral transduction of an MLL-ENL fusion protein into fetal liver cells and subsequent transplantation into syngeneic mice.
  • Blasts were harvested from moribund animals and myeloid lineage confirmed by immunophenotyping.
  • In contrast there was no difference in leukemic burden between Ara-C treated, dox treated or control animals in AML without Flt3 ITD (p = 0.2833).
  • These results suggest AML patients with Flt3 ITD may benefit more from high-dose cytarabine regimens then anthracyclines.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961434.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


92. Kotru M, Batra M, Gomber S, Rusia U: Transient thrombocytosis with megathrombocytes in a case of acute myeloblastic leukemia. Indian J Pathol Microbiol; 2009 Jan-Mar;52(1):113-4
MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Transient thrombocytosis with megathrombocytes in a case of acute myeloblastic leukemia.
  • It is rarely seen in acute leukemia.
  • A 12-year-old girl with acute myeloblastic leukemia (FAB M2) in remission presented with pyoderma.
  • This case has been presented because thrombocytosis is rare in AML and its appearance calls for a close follow-up.
  • [MeSH-major] Leukemia, Myeloid, Acute / complications. Leukemia, Myeloid, Acute / pathology. Thrombocytosis / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19136802.001).
  • [ISSN] 0974-5130
  • [Journal-full-title] Indian journal of pathology & microbiology
  • [ISO-abbreviation] Indian J Pathol Microbiol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] India
  •  go-up   go-down


93. Horikoshi A, Takei K, Iriyama N, Uenogawa K, Ishizuka H, Shiraiwa H, Hosokawa Y, Sawada S, Kitoh T: Effect of L-asparaginase combined with vincristine and prednisolone on acute myeloblastic leukemia (M0) associated with non-Hodgkin lymphoma. Acta Haematol; 2009;122(1):54-7
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effect of L-asparaginase combined with vincristine and prednisolone on acute myeloblastic leukemia (M0) associated with non-Hodgkin lymphoma.
  • She was eventually diagnosed as having acute myeloblastic leukemia (AML;.
  • M0) with non-Hodgkin lymphoma (NHL).
  • We investigated the therapeutic efficacy of L-asparaginase (L-Asp), vincristine and prednisolone for both her AML and NHL.
  • Asparagine synthetase (AS) activity in her AML blast cells was undetectable.
  • A lymph node biopsy specimen revealed NHL of the marginal zone B cell type.
  • Complete remission (CR) of AML and NHL was achieved.
  • CR of the AML lasted for 18 months without further consolidation therapy.
  • We conclude that L-Asp can be an effective drug for the treatment of AML in which blasts are negative for AS.
  • [MeSH-major] Asparaginase / therapeutic use. Leukemia, Myeloid, Acute / drug therapy. Lymphoma, Non-Hodgkin / drug therapy. Prednisolone / therapeutic use. Vincristine / therapeutic use

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2009 S. Karger AG, Basel
  • (PMID = 19816010.001).
  • [ISSN] 1421-9662
  • [Journal-full-title] Acta haematologica
  • [ISO-abbreviation] Acta Haematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 9PHQ9Y1OLM / Prednisolone; EC 3.5.1.1 / Asparaginase; EC 6.3.1.1 / Aspartate-Ammonia Ligase
  •  go-up   go-down


94. Arnaud B, Douet-Guilbert N, Morel F, Le Bris MJ, Herry A, Banzakour S, Bourquard P, Morice P, Le Calvez G, Marion V, Abgrall JF, Berthou C, De Braekeleer M: Screening by fluorescence in situ hybridization for MLL status at diagnosis in 239 unselected patients with acute myeloblastic leukemia. Cancer Genet Cytogenet; 2005 Sep;161(2):110-5
MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Screening by fluorescence in situ hybridization for MLL status at diagnosis in 239 unselected patients with acute myeloblastic leukemia.
  • A large number of abnormalities involving the MLL gene have been associated with hematological malignancies, including acute myeloblastic leukemias (AML).
  • Given the overall unfavorable prognosis of AML with an MLL abnormality, its reliable and accurate detection is needed for informed treatment decision.
  • We therefore investigated the occurrence of MLL abnormalities in 239 unselected consecutive AML patients, using conventional cytogenetic and fluorescent in situ hybridization (FISH) analyses.
  • MLL abnormalities were more frequently found in AML-M5 and M4, mainly as rearrangements, and in AML-M2, mainly as overrepresentation.
  • All M2, M4, and M5 AML patients without known recurrent translocations, such as t(8;21) and inv(16), should be investigated by FISH with an MLL probe because it allows the detection of MLL rearrangement that would go undetected by conventional cytogenetics and because it has the ability of detecting multiple copies of the MLL gene in, for example, marker chromosomes and double minutes.
  • [MeSH-major] Chromosome Aberrations. Chromosomes, Human, Pair 11. DNA-Binding Proteins / genetics. Leukemia, Myeloid, Acute / genetics. Proto-Oncogenes / genetics. Transcription Factors / genetics
  • [MeSH-minor] Adult. Aged. Female. Histone-Lysine N-Methyltransferase. Humans. In Situ Hybridization, Fluorescence. Infant, Newborn. Male. Middle Aged. Myeloid-Lymphoid Leukemia Protein

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16102580.001).
  • [ISSN] 0165-4608
  • [Journal-full-title] Cancer genetics and cytogenetics
  • [ISO-abbreviation] Cancer Genet. Cytogenet.
  • [Language] eng
  • [Publication-type] Comparative Study; Evaluation Studies; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA-Binding Proteins; 0 / MLL protein, human; 0 / Transcription Factors; 149025-06-9 / Myeloid-Lymphoid Leukemia Protein; EC 2.1.1.43 / Histone-Lysine N-Methyltransferase
  •  go-up   go-down


95. Chen CY, Jia JH, Zhang MX, Meng YS, Kong DX, Pan XL, Yu XP: Proteomic analysis on multi-drug resistant cells HL-60/DOX of acute myeloblastic leukemia. Chin J Physiol; 2005 Sep 30;48(3):115-20
MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Proteomic analysis on multi-drug resistant cells HL-60/DOX of acute myeloblastic leukemia.
  • Multi-drug resistance (MDR) is an important factor that causes treatment failure in acute leukemia.
  • The purpose of this study is to investigate differentially expressed proteins in the multi-drug resistant acute myeloblastic leukemia (AML) cell line HL-60/DOX and the drug sensitive cell line HL-60, and to identify new potential multi-drug resistant related molecules with the proteomic approach.
  • Two-dimensional gel electrophoresis (2-DE) maps of the proteins, extracted from two AML cell lines, HL-60/DOX and HL-60, were established respectively.
  • They involved the protein disulfide isomerase precursor (PDI), the proteasomes alpha1 and other proteins which are related to drug resistance or cell metabolism, but their functional significances are required further investigation.
  • Nevertheless, it is clear that this proteomic approach for studing the biology and development of MDR is a prerequisite in leukemia.
  • [MeSH-major] Drug Resistance, Multiple. Leukemia, Myeloid, Acute / physiopathology. Proteomics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Chin J Physiol. 2005 Dec 31;48(4):230
  • (PMID = 16304837.001).
  • [ISSN] 0304-4920
  • [Journal-full-title] The Chinese journal of physiology
  • [ISO-abbreviation] Chin J Physiol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China (Republic : 1949- )
  •  go-up   go-down


96. Tatetsu H, Asou N, Nakamura M, Hanaoka N, Matsuno F, Horikawa K, Mitsuya H: Torsades de pointes upon fluconazole administration in a patient with acute myeloblastic leukemia. Am J Hematol; 2006 May;81(5):366-9
Hazardous Substances Data Bank. FLUCONAZOLE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Torsades de pointes upon fluconazole administration in a patient with acute myeloblastic leukemia.
  • Prolonged QT syndrome often causes torsades de pointes (Tdp), a potentially lethal arrhythmia.
  • [MeSH-major] Antifungal Agents / adverse effects. Fluconazole / adverse effects. Leukemia, Myeloid, Acute / complications. Mycoses / drug therapy. Opportunistic Infections / drug therapy. Torsades de Pointes / chemically induced

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • MedlinePlus Health Information. consumer health - Fungal Infections.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2006 Wiley-Liss, Inc.
  • (PMID = 16628725.001).
  • [ISSN] 0361-8609
  • [Journal-full-title] American journal of hematology
  • [ISO-abbreviation] Am. J. Hematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antifungal Agents; 8VZV102JFY / Fluconazole
  •  go-up   go-down


97. Entz-Werle N, Suciu S, van der Werff ten Bosch J, Vilmer E, Bertrand Y, Benoit Y, Margueritte G, Plouvier E, Boutard P, Vandecruys E, Ferster A, Lutz P, Uyttebroeck A, Hoyoux C, Thyss A, Rialland X, Norton L, Pages MP, Philippe N, Otten J, Behar C, EORTC Children Leukemia Group: Results of 58872 and 58921 trials in acute myeloblastic leukemia and relative value of chemotherapy vs allogeneic bone marrow transplantation in first complete remission: the EORTC Children Leukemia Group report. Leukemia; 2005 Dec;19(12):2072-81
Hazardous Substances Data Bank. NOVANTRONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Results of 58872 and 58921 trials in acute myeloblastic leukemia and relative value of chemotherapy vs allogeneic bone marrow transplantation in first complete remission: the EORTC Children Leukemia Group report.
  • The first EORTC (European Organization of Research and Treatment of Cancer) acute myeloblastic leukemia (AML) pilot study (58872) was conducted between January 1988 and December 1991.
  • It indicated that mitoxantrone could be substituted for conventional anthracyclines in the treatment of childhood AML without inducing cardiotoxicity.
  • In patients with or without a donor, the 7-year disease-free survival (DFS) rate was 63 (8) and 57% (5%) and the 7-year survival rate was 78 (7) and 65% (5%), respectively.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Antineoplastic Protocols / standards. Bone Marrow Transplantation. Leukemia, Myeloid, Acute / therapy

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • MedlinePlus Health Information. consumer health - Bone Marrow Transplantation.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16136166.001).
  • [ISSN] 0887-6924
  • [Journal-full-title] Leukemia
  • [ISO-abbreviation] Leukemia
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / 5U10-CA11488-18; United States / NCI NIH HHS / CA / 5U10-CA11488-35
  • [Publication-type] Clinical Trial, Phase III; Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] BZ114NVM5P / Mitoxantrone; ZRP63D75JW / Idarubicin
  •  go-up   go-down


98. Wiktor-Jedrzejczyk W, Rokicka M, Urbanowska E, Torosian T, Graczyk-Pol E, Tomaszewska A, Król M, Paluszewska M, Gronkowska A, Ziarkiewicz-Wróblewska B, Jółkowska J, Witt M: Simultaneous transplantation of two allogeneic units of cord blood in an adult patient with acute myeloblastic leukemia: a case report. Arch Immunol Ther Exp (Warsz); 2005 Jul-Aug;53(4):364-8
MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Simultaneous transplantation of two allogeneic units of cord blood in an adult patient with acute myeloblastic leukemia: a case report.
  • However, the use of cord blood as a source of cells for transplantation is limited by its cell number, usually below 1 billion, which allows for routine transplantation only in children weighting less than 30 kg, while most potential recipients possess a higher body mass.
  • This led to the idea of the simultaneous use of several units of cord blood which, combined, would fulfill the requirements for the necessary cell number for an adult recipient.
  • MATERIAL/METHODS: We attempted to simultaneously transplant an adult patient with refractory acute myeloblastic leukemia utilizing two different cord blood units, one fully matched and one mismatched at one locus.
  • RESULTS: The patient became reconstituted with only one unit, the mismatched, as determined using microsatellite markers, and had no signs of relapse of leukemia.
  • [MeSH-major] Cord Blood Stem Cell Transplantation / methods. Leukemia, Myeloid, Acute / therapy

  • Genetic Alliance. consumer health - Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16088322.001).
  • [ISSN] 0004-069X
  • [Journal-full-title] Archivum immunologiae et therapiae experimentalis
  • [ISO-abbreviation] Arch. Immunol. Ther. Exp. (Warsz.)
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Poland
  •  go-up   go-down


99. Savva NN, Belevtsev MV, Savitskiĭ VP, Migal' NV, Movchan LV, Aleĭnikova OV: [Role of three-color flow cytofluorometry in the algorithm for detection of minimal residual disease in children with acute lymphoblastic and acute myeloblastic leukemia]. Klin Lab Diagn; 2009 Dec;(12):15-8
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Role of three-color flow cytofluorometry in the algorithm for detection of minimal residual disease in children with acute lymphoblastic and acute myeloblastic leukemia].
  • Three-color flow cytofluorometry (FCF) was used to identify minimal residual disease in 124 patients with acute lymphoblastic leukemia (ALL) treated in accordance with the ALL-myeloblastic leukemia (MBL)-2002/2008 protocol and 36 patients with MBL treated under the MBL-MM-2000 protocol.
  • It was shown that approximately a fifth of children with ALL, 3-color FCF could not monitor minimal residual disease, which required the use of 4- or more-color FCF and parallel determination in these MBL samples by molecular genetic methods.
  • [MeSH-major] Leukemia, Myeloid, Acute / diagnosis. Neoplasm, Residual / diagnosis. Precursor Cell Lymphoblastic Leukemia-Lymphoma / diagnosis

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20140998.001).
  • [ISSN] 0869-2084
  • [Journal-full-title] Klinicheskaia laboratornaia diagnostika
  • [ISO-abbreviation] Klin. Lab. Diagn.
  • [Language] rus
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  •  go-up   go-down


100. Gutierrez-Aguirre CH, Cantú-Rodríguez OG, Gonzalez-Llano O, Salazar-Riojas R, Martinez-González O, Jaime-Pérez JC, Morales-Toquero A, Tarín-Arzaga LC, Ruiz-Argüelles GJ, Gómez-Almaguer D: Non-myeloablative hematopoietic stem cell transplantation is of limited value in advanced or refractory acute myeloblastic leukemia. The Mexican experience. Hematology; 2007 Jun;12(3):193-7
Hazardous Substances Data Bank. CYCLOSPORIN A .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Non-myeloablative hematopoietic stem cell transplantation is of limited value in advanced or refractory acute myeloblastic leukemia. The Mexican experience.
  • Allogeneic hematopoietic stem cell transplantation (HSCT) is an effective strategy for preventing relapse of acute myelogenous leukemia (AML).
  • We analyzed the outcome of 31 primary AML patients who received a reduced-intensity conditioning regimen for allogeneic HSCT in first or second remission.
  • Thirty-one AML patients, 20 in first complete remission (FCR), 8 in second complete remission (SCR) and 3 in a partial remission (SPR) were included.
  • All patients received cyclosporine-A (CsA) and methotrexate as graft vs. host disease (GvHD) prophylaxis.
  • All patients showed myeloid engraftment (neutrophils >0.5 x 10(9)/l) after a median of 13 days in FCR group and 15 days in SCR group.
  • Conclusions. Reduced-intensity conditioning followed by allogeneic HSCT can induce stable remission in primary AML patients transplanted in FCR.
  • A high relapse rate was documented in patients with refractory or relapsed AML.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Hematopoietic Stem Cell Transplantation / methods. Leukemia, Myeloid, Acute / therapy
  • [MeSH-minor] Adolescent. Adult. Busulfan / administration & dosage. Child. Child, Preschool. Cyclophosphamide / administration & dosage. Cyclosporine / administration & dosage. Graft Survival. Graft vs Host Disease / drug therapy. Graft vs Host Disease / prevention & control. Humans. Mexico. Middle Aged. Recurrence. Salvage Therapy / methods. Transplantation Conditioning / methods. Treatment Outcome. Vidarabine / administration & dosage. Vidarabine / analogs & derivatives

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • Hazardous Substances Data Bank. FLUDARABINE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. BUSULFAN .
  • Hazardous Substances Data Bank. VIDARABINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17558694.001).
  • [ISSN] 1607-8454
  • [Journal-full-title] Hematology (Amsterdam, Netherlands)
  • [ISO-abbreviation] Hematology
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 83HN0GTJ6D / Cyclosporine; 8N3DW7272P / Cyclophosphamide; FA2DM6879K / Vidarabine; G1LN9045DK / Busulfan; P2K93U8740 / fludarabine
  •  go-up   go-down






Advertisement